KEYUR PRAVINCHANDRAPATELKEYUR PRAVINCHANDRA PATEL9606PATEL, KEYUR PRAVINCHANDRAAssociate Professorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson6565 MD Anderson BlvdHouston77030TXAuthorship 1897713Authorship 1912842Authorship 1922002Authorship 1931616Authorship 1937533Authorship 1944031222605576Borthakur G, Kantarjian H, Patel KP, Ravandi F, Qiao W, Faderl S, Kadia T, Luthra R, Pierce S, Cortes JECancerImpact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia. Cancer. 2012 Dec 01; 118(23):5819-22.Cancer2012-05-17T00:00:002012Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia.23774633Takahashi K, Jabbour E, Wang X, Luthra R, Bueso-Ramos C, Patel K, Pierce S, Yang H, Wei Y, Daver N, Faderl S, Ravandi F, Estrov Z, Cortes J, Kantarjian H, Garcia-Manero GLeukemiaDynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML. Leukemia. 2013 Oct; 27(10):2081-3.Leukemia2013-06-07T00:00:002013Dynamic acquisition of FLT3 or RAS alterations drive a subset of patients with lower risk MDS to secondary AML.23810757Singh RR, Patel KP, Routbort MJ, Reddy NG, Barkoh BA, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, Aldape KD, Luthra RThe Journal of molecular diagnostics : JMDClinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes. J Mol Diagn. 2013 Sep; 15(5):607-22.J Mol Diagn2013-06-26T00:00:002013Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes.24619758Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, Aldape K, Patel KPAmerican journal of clinical pathologyQuantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. Am J Clin Pathol. 2014 Apr; 141(4):559-72.Am J Clin Pathol2014-04-01T00:00:002014Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing.HematopathologyLeukemiaMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorRAJYALAKSHMILUTHRARAJYALAKSHMI LUTHRA8592LUTHRA, RAJYALAKSHMIProfessorL JEFFREYMEDEIROSL JEFFREY MEDEIROS8762MEDEIROS, L JEFFREYProfessorSRDANVERSTOVSEKSRDAN VERSTOVSEK8781VERSTOVSEK, SRDANProfessorELIAS JOSEPHJABBOURELIAS JOSEPH JABBOUR9124JABBOUR, ELIAS JOSEPHAssociate ProfessorCOURTNEYDINARDOCOURTNEY DINARDO9868DINARDO, COURTNEYAssistant ProfessorGUILLERMOGARCIA-MANEROGUILLERMO GARCIA-MANERO8853GARCIA-MANERO, GUILLERMOProfessor3.93530.00795778573research areas7.878860.0295626205coauthor of515.91345.371960similar to11292selected publicationsAuthorship 2226012Authorship 2291071Authorship 2312841Authorship 2315674Authorship 2319563Authorship 2320593Authorship 23304111Authorship 2332824Authorship 2338003Authorship 2340757Authorship 234505516341048Herling M, Patel KA, Khalili J, Schlette E, Kobayashi R, Medeiros LJ, Jones DLeukemiaTCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state. Leukemia. 2006 Feb; 20(2):280-5.Leukemia2006-02-01T00:00:002006TCL1 shows a regulated expression pattern in chronic lymphocytic leukemia that correlates with molecular subtypes and proliferative state.21173122Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra RAmerican journal of clinical pathologyAcute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol. 2011 Jan; 135(1):35-45.Am J Clin Pathol2011-01-01T00:00:002011Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features.22035742Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra RClinical lymphoma, myeloma & leukemiaArray comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun; 11 Suppl 1:S17-24.Clin Lymphoma Myeloma Leuk2011-05-05T00:00:002011Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.22540299Deqin M, Chen Z, Nero C, Patel KP, Daoud EM, Cheng H, Djordjevic B, Broaddus RR, Medeiros LJ, Rashid A, Luthra RArchives of pathology & laboratory medicineSomatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas. Arch Pathol Lab Med. 2012 May; 136(5):510-6.Arch Pathol Lab Med2012-05-01T00:00:002012Somatic deletions of the polyA tract in the 3' untranslated region of epidermal growth factor receptor are common in microsatellite instability-high endometrial and colorectal carcinomas.22706871Verma S, Greaves WO, Ravandi F, Reddy N, Bueso-Ramos CE, O'Brien S, Thomas DA, Kantarjian H, Medeiros LJ, Luthra R, Patel KPAmerican journal of clinical pathologyRapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay. Am J Clin Pathol. 2012 Jul; 138(1):153-6.Am J Clin Pathol2012-07-01T00:00:002012Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay.22936064Patel KP, Khokhar FA, Muzzafar T, James You M, Bueso-Ramos CE, Ravandi F, Pierce S, Medeiros LJModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncTdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol. 2013 Feb; 26(2):195-203.Mod Pathol2012-08-31T00:00:002012TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation.23273605Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, Aldape KD, Medeiros LJ, Luthra RThe Journal of molecular diagnostics : JMDFrequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn. 2013 Mar; 15(2):220-6.J Mol Diagn2012-12-27T00:00:002012Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma.23495765Al-Ibraheemi A, Kanagal-Shamanna R, Patel KP, Konoplev SN, Mehta P, Medeiros LJ, Miranda RNJournal of cutaneous pathologyPhenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity. J Cutan Pathol. 2013 Jun; 40(6):573-9.J Cutan Pathol2013-03-15T00:00:002013Phenotypic evolution in a case of peripheral T-cell lymphoma suggests the presence of tumor heterogeneity.23763914Jain P, Le X, Young KH, Patel KP, Wang S, Pei L, Barron LL, Abruzzo L, O'Brien SClinical lymphoma, myeloma & leukemiaSequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13(5):606-9.Clin Lymphoma Myeloma Leuk2013-06-10T00:00:002013Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.23787392Ok CY, Hasserjian RP, Fox PS, Stingo F, Zuo Z, Young KH, Patel K, Medeiros LJ, Garcia-Manero G, Wang SALeukemiaApplication of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia. 2014 Jan; 28(1):185-9.Leukemia2013-06-21T00:00:002013Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia.24151865Aung PP, Climent F, Muzzafar T, Curry JL, Patel KP, Servitje O, Prieto VG, Duvic M, Jaffe ES, Torres-Cabala CAJournal of cutaneous pathologyImmunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases. J Cutan Pathol. 2014 Jan; 41(1):51-7.J Cutan Pathol2013-11-14T00:00:002013Immunophenotypic shift of CD4 and CD8 antigen expression in primary cutaneous T-cell lymphomas: a clinicopathologic study of three cases.Authorship 2545091Authorship 2572051Authorship 2579542Authorship 2592622Authorship 26045118Authorship 2612868Authorship 2616481220181819Patel KP, Pan Q, Wang Y, Maitta RW, Du J, Xue X, Lin J, Ratech HThe Journal of molecular diagnostics : JMDComparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements. J Mol Diagn. 2010 Mar; 12(2):226-37.J Mol Diagn2010-03-01T00:00:002010Comparison of BIOMED-2 versus laboratory-developed polymerase chain reaction assays for detecting T-cell receptor-gamma gene rearrangements.21889610Patel KP, Barkoh BA, Chen Z, Ma D, Reddy N, Medeiros LJ, Luthra RThe Journal of molecular diagnostics : JMDDiagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis. J Mol Diagn. 2011 Nov; 13(6):678-86.J Mol Diagn2011-09-01T00:00:002011Diagnostic testing for IDH1 and IDH2 variants in acute myeloid leukemia an algorithmic approach using high-resolution melting curve analysis.22809282Nicholson KM, Patel KP, Duvic M, Prieto VG, Tetzlaff MTJournal of cutaneous pathologyBi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. J Cutan Pathol. 2012 Sep; 39(9):866-71.J Cutan Pathol2012-07-19T00:00:002012Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature.23537216Collier P, Patel K, Waeltz P, Rupar M, Luthra R, Liu PC, Hollis G, Huber R, Verstovsek S, Burn TCGenetic testing and molecular biomarkersValidation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples. Genet Test Mol Biomarkers. 2013 May; 17(5):429-37.Genet Test Mol Biomarkers2013-03-28T00:00:002013Validation of standards for quantitative assessment of JAK2 c.1849G>T (p.V617F) allele burden analysis in clinical samples.23907151Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, Aldape KD, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerkel GA, Medeiros LJ, Luthra R, Patel KPModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncNext-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod Pathol. 2014 Feb; 27(2):314-27.Mod Pathol2013-08-02T00:00:002013Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics.24627528Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, Stingo FC, Patel KP, Mehrotra M, Bueso-Ramos C, Young KH, Dinardo CD, Verstovsek S, Tiu RV, Bagg A, Hsi ED, Arber DA, Foucar K, Luthra R, Orazi ABloodAtypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014 Apr 24; 123(17):2645-51.Blood2014-03-13T00:00:002014Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.25128227Mehrotra M, Medeiros LJ, Luthra R, Sargent RL, Yao H, Barkoh BA, Singh R, Patel KPHuman pathologyIdentification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma. Hum Pathol. 2014 Oct; 45(10):1995-2005.Hum Pathol2014-06-30T00:00:002014Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.Authorship 2673692Authorship 2705933Authorship 271686817683193Lisovsky M, Patel K, Cymes K, Chase D, Bhuiya T, Morgenstern NArchives of pathology & laboratory medicineImmunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6. Arch Pathol Lab Med. 2007 Aug; 131(8):1304-11.Arch Pathol Lab Med2007-08-01T00:00:002007Immunophenotypic characterization of anal gland carcinoma: loss of p63 and cytokeratin 5/6.22642896Singh RR, Bains A, Patel KP, Rahimi H, Barkoh BA, Paladugu A, Bisrat T, Ravandi-Kashani F, Cortes JE, Kantarjian HM, Medeiros LJ, Luthra RThe Journal of molecular diagnostics : JMDDetection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis. J Mol Diagn. 2012 Jul; 14(4):336-45.J Mol Diagn2012-05-27T00:00:002012Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.23121011Greaves WO, Verma S, Bisrat T, Strati P, Rahimi H, Paladugu AV, Luthra R, Patel KP, Medeiros LJ, Yao H, Pierce S, Bueso-Ramos CE, Verstovsek SLeukemia & lymphomaTP53 mutation is rare in primary myelofibrosis. Leuk Lymphoma. 2013 Jul; 54(7):1552.Leuk Lymphoma2012-11-30T00:00:002012TP53 mutation is rare in primary myelofibrosis.Authorship 274782224068492Takahashi K, Patel KP, Kantarjian H, Luthra R, Pierce S, Cortes J, Verstovsek SBloodJAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms. Blood. 2013 Nov 28; 122(23):3784-6.Blood2013-09-25T00:00:002013JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.Authorship 2877972Authorship 2878062Authorship 2883859Authorship 2896705Authorship 2900004Authorship 29090628Authorship 2921648Authorship 2935772Authorship 29361613Authorship 2938401Authorship 2941893Authorship 2943052Authorship 2946868Authorship 2948464Authorship 2949055Authorship 2951832Authorship 2953212Authorship 2965014Authorship 2967398Authorship 2990242Authorship 29949412Authorship 3007904Authorship 3011064Authorship 3013932Authorship 30179312Authorship 3029932Authorship 30363712Authorship 3037388Authorship 3040375Authorship 3050347Authorship 3051482Authorship 305785124004182Jain P, Kantarjian H, Patel K, Faderl S, Garcia-Manero G, Benjamini O, Borthakur G, Pemmaraju N, Kadia T, Daver N, Nazha A, Luthra R, Pierce S, Cortes J, Ravandi FLeukemia & lymphomaMutated NPM1 in patients with acute myeloid leukemia in remission and relapse. Leuk Lymphoma. 2014 Jun; 55(6):1337-44.Leuk Lymphoma2013-10-09T00:00:002013Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse.24138309DiNardo CD, Patel KP, Garcia-Manero G, Luthra R, Pierce S, Borthakur G, Jabbour E, Kadia T, Pemmaraju N, Konopleva M, Faderl S, Cortes J, Kantarjian HM, Ravandi FLeukemia & lymphomaLack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymphoma. 2014 Aug; 55(8):1925-9.Leuk Lymphoma2014-02-04T00:00:002014Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.24142997Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, Barkoh BA, Kanagal-Shamanna R, Ravandi F, Cortes JE, Kantarjian HM, Medeiros LJ, Singh RRHaematologicaNext-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica. 2014 Mar; 99(3):465-73.Haematologica2013-10-18T00:00:002013Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.24446873Mehrotra M, Luthra R, Ravandi F, Sargent RL, Barkoh BA, Abraham R, Mishra BM, Medeiros LJ, Patel KPLeukemia & lymphomaIdentification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization. Leuk Lymphoma. 2014 Nov; 55(11):2538-48.Leuk Lymphoma2014-11-01T00:00:002014Identification of clinically important chromosomal aberrations in acute myeloid leukemia by array-based comparative genomic hybridization.24743221Loghavi S, Curry JL, Torres-Cabala CA, Ivan D, Patel KP, Mehrotra M, Bassett R, Prieto VG, Tetzlaff MTModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMelanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature. Mod Pathol. 2014 Nov; 27(11):1468-78.Mod Pathol2014-04-18T00:00:002014Melanoma arising in association with blue nevus: a clinical and pathologic study of 24 cases and comprehensive review of the literature.24854988Falchi L, Mehrotra M, Newberry KJ, Lyle LM, Lu G, Patel KP, Luthra R, Popat U, Verstovsek SLeukemiaETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant. Leukemia. 2014 Oct; 28(10):2090-2.Leukemia2014-05-23T00:00:002014ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.24864220Korivi BR, Jensen CT, Patnana M, Patel KP, Bathala TKCase reports in radiologyA rare presentation of lymphoma of the cervix with cross-sectional imaging correlation. Case Rep Radiol. 2014; 2014:157268.Case Rep Radiol2014-04-17T00:00:002014A rare presentation of lymphoma of the cervix with cross-sectional imaging correlation.25148578Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, Aldape KD, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MAThe Journal of investigative dermatologyBeyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol. 2015 Feb; 135(2):508-515.J Invest Dermatol2014-08-22T00:00:002014Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.25281355Loghavi S, Zuo Z, Ravandi F, Kantarjian HM, Bueso-Ramos C, Zhang L, Singh RR, Patel KP, Medeiros LJ, Stingo F, Routbort M, Cortes J, Luthra R, Khoury JDJournal of hematology & oncologyClinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations. J Hematol Oncol. 2014 Oct 04; 7:74.J Hematol Oncol2014-10-04T00:00:002014Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.25314059Singh RR, Patel KP, Routbort MJ, Aldape K, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra RBritish journal of cancerClinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. Br J Cancer. 2014 Nov 11; 111(10):2014-23.Br J Cancer2014-10-14T00:00:002014Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.25546882Patel KPAmerican journal of clinical pathologyMore accurate ways to measure tumor cellularity. The author's reply. Am J Clin Pathol. 2014 Dec; 142(6):880.Am J Clin Pathol2014-12-01T00:00:002014More accurate ways to measure tumor cellularity. The author's reply.25573287Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, Young KH, Kantarjian HM, Medeiros LJ, Luthra R, Wang SALeukemia researchMutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015 Mar; 39(3):348-54.Leuk Res2014-12-20T00:00:002014Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.25583766Yin CC, Jain N, Mehrotra M, Zhagn J, Protopopov A, Zuo Z, Pemmaraju N, DiNardo C, Hirsch-Ginsberg C, Wang SA, Medeiros LJ, Chin L, Patel KP, Ravandi F, Futreal A, Bueso-Ramos CEJournal of the National Comprehensive Cancer Network : JNCCNIdentification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia. J Natl Compr Canc Netw. 2015 Jan; 13(1):19-22.J Natl Compr Canc Netw2015-01-01T00:00:002015Identification of a novel fusion gene, IRF2BP2-RARA, in acute promyelocytic leukemia.25630528Kazmi SM, Pemmaraju N, Patel KP, Cohen PR, Daver N, Tran KM, Ravandi F, Duvic M, Garcia-Manero G, Pierce S, Nazha A, Borthakur G, Kantarjian H, Cortes JClinical lymphoma, myeloma & leukemiaCharacteristics of Sweet Syndrome in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15(6):358-363.Clin Lymphoma Myeloma Leuk2014-12-24T00:00:002014Characteristics of Sweet Syndrome in patients with acute myeloid leukemia.25634750Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, Aldape KD, Medeiros LJ, Routbort MJThe American journal of surgical pathologyComparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry. Am J Surg Pathol. 2015 Apr; 39(4):454-61.Am J Surg Pathol2015-04-01T00:00:002015Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.25666664de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, Gangar P, Prieto VG, Medeiros LJ, Duvic M, Tetzlaff MTHuman pathologyShared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol. 2015 Apr; 46(4):558-69.Hum Pathol2014-12-31T00:00:002014Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin.25695693Goswami RS, Patel KP, Singh RR, Meric-Bernstam F, Kopetz ES, Subbiah V, Alvarez RH, Davies MA, Jabbar KJ, Roy-Chowdhuri S, Lazar AJ, Medeiros LJ, Broaddus RR, Luthra R, Routbort MJClinical cancer research : an official journal of the American Association for Cancer ResearchHotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clin Cancer Res. 2015 Jun 01; 21(11):2644-51.Clin Cancer Res2015-02-18T00:00:002015Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors.25754356Stockman DL, Curry JL, Torres-Cabala CA, Watson IR, Siroy AE, Bassett RL, Zou L, Patel KP, Luthra R, Davies MA, Wargo JA, Routbort MA, Broaddus RR, Prieto VG, Lazar AJ, Tetzlaff MTJournal of cutaneous pathologyUse of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations. J Cutan Pathol. 2015 May; 42(5):308-17.J Cutan Pathol2015-03-24T00:00:002015Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.25795921Daver N, Cortes J, Ravandi F, Patel KP, Burger JA, Konopleva M, Kantarjian HBloodSecondary mutations as mediators of resistance to targeted therapy in leukemia. Blood. 2015 May 21; 125(21):3236-45.Blood2015-03-20T00:00:002015Secondary mutations as mediators of resistance to targeted therapy in leukemia.25808231Jain P, Verstovsek S, Loghavi S, Jorgensen JL, Patel KP, Estrov Z, Fayad L, Pemmaraju NAmerican journal of hematologyDurable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. Am J Hematol. 2015 Nov; 90(11):1091-2.Am J Hematol2015-04-29T00:00:002015Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome.25863335Meric-Bernstam F, Johnson A, Holla V, Bailey AM, Brusco L, Chen K, Routbort M, Patel KP, Zeng J, Kopetz S, Davies MA, Piha-Paul SA, Hong DS, Eterovic AK, Tsimberidou AM, Broaddus R, Bernstam EV, Shaw KR, Mendelsohn J, Mills GBJournal of the National Cancer InstituteA decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).J Natl Cancer Inst2015-04-11T00:00:002015A decision support framework for genomically informed investigational cancer therapy.25952993Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Peng J, Tang G, Goswami M, Young KH, Singh R, Medeiros LJ, Kantarjian HM, Luthra R, Wang SAJournal of hematology & oncologyTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. J Hematol Oncol. 2015 May 08; 8:45.J Hematol Oncol2015-05-08T00:00:002015TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.25999449Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KPBloodInsights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood. 2015 May 21; 125(21):3360-3.Blood2015-05-21T00:00:002015Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.26015395Boland GM, Piha-Paul SA, Subbiah V, Routbort M, Herbrich SM, Baggerly K, Patel KP, Brusco L, Horombe C, Naing A, Fu S, Hong DS, Janku F, Johnson A, Broaddus R, Luthra R, Shaw K, Mendelsohn J, Mills GB, Meric-Bernstam FOncotargetClinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.Oncotarget2015-08-21T00:00:002015Clinical next generation sequencing to identify actionable aberrations in a phase I program.26016821DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Pierce S, Garcia-Manero G, Cortes J, Kantarjian HAmerican journal of hematologyCharacteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol. 2015 Aug; 90(8):732-6.Am J Hematol2015-08-01T00:00:002015Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML.26027540Mehrotra M, Patel KP, Chen T, Miranda RN, Wang Y, Zuo Z, Muddasani R, Mishra BM, Abraham R, Luthra R, Lu GClinical lymphoma, myeloma & leukemiaGenomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion. Clin Lymphoma Myeloma Leuk. 2015 Aug; 15(8):496-505.e1-2.Clin Lymphoma Myeloma Leuk2015-04-03T00:00:002015Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion.26058727Tetzlaff MT, Pattanaprichakul P, Wargo J, Fox PS, Patel KP, Estrella JS, Broaddus RR, Williams MD, Davies MA, Routbort MJ, Lazar AJ, Woodman SE, Hwu WJ, Gershenwald JE, Prieto VG, Torres-Cabala CA, Curry JLHuman pathologyUtility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. Hum Pathol. 2015 Aug; 46(8):1101-10.Hum Pathol2015-05-06T00:00:002015Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma.26124496Patel KP, Newberry KJ, Luthra R, Jabbour E, Pierce S, Cortes J, Singh R, Mehrotra M, Routbort MJ, Luthra M, Manshouri T, Santos FP, Kantarjian H, Verstovsek SBloodCorrelation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 Aug 06; 126(6):790-7.Blood2015-06-29T00:00:002015Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.26230354Roy-Chowdhuri S, Goswami RS, Chen H, Patel KP, Routbort MJ, Singh RR, Broaddus RR, Barkoh BA, Manekia J, Yao H, Medeiros LJ, Staerkel G, Luthra R, Stewart JCancer cytopathologyFactors affecting the success of next-generation sequencing in cytology specimens. Cancer Cytopathol. 2015 Nov; 123(11):659-68.Cancer Cytopathol2015-07-31T00:00:002015Factors affecting the success of next-generation sequencing in cytology specimens.26300976Gu J, Patel KP, Bai B, Liu CH, Tang G, Kantarjian HM, Tang Z, Abraham R, Luthra R, Medeiros LJ, Lin P, Lu XMolecular cytogeneticsDouble inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Mol Cytogenet. 2015; 8:68.Mol Cytogenet2015-08-19T00:00:002015Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression.26438153Estrella JS, Tetzlaff MT, Bassett RL, Patel KP, Williams MD, Curry JL, Rashid A, Hamilton SR, Broaddus RRMolecular cancer therapeuticsAssessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing. Mol Cancer Ther. 2015 Dec; 14(12):2887-95.Mol Cancer Ther2015-10-05T00:00:002015Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.26486734Roy-Chowdhuri S, de Melo Gagliato D, Routbort MJ, Patel KP, Singh RR, Broaddus R, Lazar AJ, Sahin A, Alvarez RH, Moulder S, Wheler JJ, Janku F, Gonzalez-Angulo AM, Chavez-MacGregor M, Valero V, Ueno NT, Mills G, Mendelsohn J, Yao H, Aldape K, Luthra R, Meric-Bernstam FAmerican journal of clinical pathologyMultigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.Am J Clin Pathol2015-11-01T00:00:002015Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.26486739Mehrotra M, Luthra R, Singh RR, Barkoh BA, Galbincea J, Mehta P, Goswami RS, Jabbar KJ, Loghavi S, Medeiros LJ, Verstovsek S, Patel KPAmerican journal of clinical pathologyClinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms. Am J Clin Pathol. 2015 Nov; 144(5):746-55.Am J Clin Pathol2015-11-01T00:00:002015Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.26547258Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero GLeukemia researchDetectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leuk Res. 2015 Dec; 39(12):1367-74.Leuk Res2015-10-19T00:00:002015Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.26687423DiNardo CD, Daver N, Jabbour E, Kadia T, Borthakur G, Konopleva M, Pemmaraju N, Yang H, Pierce S, Wierda W, Bueso-Ramos C, Patel KP, Cortes JE, Ravandi F, Kantarjian HM, Garcia-Manero GThe Lancet. HaematologySequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study. Lancet Haematol. 2015 Jan; 2(1):e12-20.Lancet Haematol2014-12-22T00:00:002014Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.27210295DiNardo CD, Bannon SA, Routbort M, Franklin A, Mork M, Armanios M, Mace EM, Orange JS, Jeff-Eke M, Churpek JE, Takahashi K, Jorgensen JL, Garcia-Manero G, Kornblau S, Bertuch A, Cheung H, Bhalla K, Futreal A, Godley LA, Patel KPClinical lymphoma, myeloma & leukemiaEvaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):417-428.e2.Clin Lymphoma Myeloma Leuk2016-04-27T00:00:002016Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).74Professor10Assistant Professor14Associate ProfessorSANAMLOGHAVISANAM LOGHAVI11842LOGHAVI, SANAMAssistant ProfessorAuthorship 3743346Authorship 3743383Authorship 3743392Authorship 843757Authorship 844109Authorship 844112Authorship 844913Authorship 845196Authorship 845273Authorship 845435Authorship 845813Authorship 846116Authorship 846448Authorship 846994Authorship 848522Authorship 848771Authorship 848789Authorship 848973Authorship 849428Authorship 850449Authorship 850913Authorship 851764Authorship 852030Authorship 852727Authorship 854089Authorship 854109Authorship 854668Authorship 855370Authorship 855604Authorship 855761Authorship 855935Authorship 856066Authorship 856179Authorship 856216Authorship 856236Authorship 858276Authorship 859936Authorship 860171Authorship 860549Authorship 860708Authorship 860949Authorship 861363Authorship 861930Authorship 862424Authorship 862750Authorship 863546Authorship 864218Authorship 864488Authorship 865353Authorship 867222Authorship 867626The Lancet HaematologySequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. The Lancet Haematology. 2:e12-e20.Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemiaClinical Lymphoma, Myeloma and LeukemiaClinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clinical Lymphoma, Myeloma and Leukemia. 16:395-403.e1.Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom MacroglobulinemiaBloodImpact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 128:504-507.Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemiaHigh-resolution melt curve analysis in cancer mutation screen. 63-69.High-resolution melt curve analysis in cancer mutation screenLeukemiaIDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression. Leukemia. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progressionAmerican Journal of HematologyImprovement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade. American Journal of Hematology. Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decadeCancerPhase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agentsJournal of Clinical OncologyFeasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trials. Journal of Clinical Oncology. 33:2753-2762.Feasibility of large-scale genomic testing to facilitate enrollment onto genomically matched clinical trialsHuman PathologyBRAF and MAP2K1 mutations in Langerhans cell histiocytosis. Human Pathology. 52:61-67.BRAF and MAP2K1 mutations in Langerhans cell histiocytosisAmerican Journal of HematologyDurable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndrome. American Journal of Hematology. 90:1091-1092.Durable remission with rituximab in a patient with an unusual variant of Castleman's disease with myelofibrosis-TAFRO syndromeAmerican Journal of HematologyAmerican Journal of Hematology. 92:E3-E4.American Journal of HematologyMutation analysis in cancer. 261-279.Mutation analysis in cancerJournal of Clinical OncologyRelapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemia. Journal of Clinical Oncology. 34:e57-e60.Relapsed refractory BRAF-negative, IGHV4-34-positive variant of hairy cell leukemiaArchives of Pathology and Laboratory MedicineTemplate for reporting results of monitoring tests for patients with chronic myelogenous leukemia (BCR-ABL1). Archives of Pathology and Laboratory Medicine. 140:672-674.Template for reporting results of monitoring tests for patients with chronic myelogenous leukemia (BCR-ABL1)Molecular CytogeneticsDouble inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression. Molecular Cytogenetics. 8.Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progressionModern PathologyAcute erythroid leukemia with. Modern Pathology. Acute erythroid leukemia withExpert Review of Molecular DiagnosticsPrinciples of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Review of Molecular Diagnostics. 1-12.Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratoryCancerTP53 mutations in newly diagnosed acute myeloid leukemia. Cancer. 122:3484-3491.TP53 mutations in newly diagnosed acute myeloid leukemiaMolecular CytogeneticsCoexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia. Molecular Cytogenetics. 9:1-10.Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemiaLeukemia and LymphomaDNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leukemia and Lymphoma. 1-5.DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemiaClinical Lymphoma, Myeloma and LeukemiaCharacteristics of sweet syndrome in patients with acute myeloid leukemia. Clinical Lymphoma, Myeloma and Leukemia. 15:358-363.Characteristics of sweet syndrome in patients with acute myeloid leukemiaBloodImpact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 127:1269-1275.Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitorsBone Marrow TransplantationBendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLL. Bone Marrow Transplantation. 52:28-33.Bendamustine added to allogeneic conditioning improves long-term outcomes in patients with CLLOncotargetMyeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 7:14251-14258.Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRASClinical Cancer ResearchHotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. Clinical Cancer Research. 21:2644-2651.Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumorsAmerican Journal of Clinical PathologyThe author's reply. American Journal of Clinical Pathology. 142:880.The author's replyBiology of Blood and Marrow TransplantationAllogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biology of Blood and Marrow Transplantation. 22:1218-1226.Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous LeukemiaLeukemia ResearchDetectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes. Leukemia Research. 39:1367-1374.Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomesJNCCN Journal of the National Comprehensive Cancer NetworkHow do we make clinical molecular testing for cancer standard of care for pathology departments?. JNCCN Journal of the National Comprehensive Cancer Network. 14:787-792.How do we make clinical molecular testing for cancer standard of care for pathology departments?Archives of Pathology and Laboratory MedicineTemplate for reporting results of biomarker testing of specimens from patients with myeloproliferative neoplasms. Archives of Pathology and Laboratory Medicine. 140:675-677.Template for reporting results of biomarker testing of specimens from patients with myeloproliferative neoplasmsClinical Lymphoma, Myeloma and LeukemiaEvaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia. Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC)Journal of HematopathologyFollicular lymphoma in situ with coincident low-grade B cell lymphoma. Journal of Hematopathology. 7:95-101.Follicular lymphoma in situ with coincident low-grade B cell lymphomaJournal of Hematology and OncologyTP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases. Journal of Hematology and Oncology. 8.TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseasesMolecular Cancer TherapeuticsAssessment of BRAF V600E status in colorectal carcinoma. Molecular Cancer Therapeutics. 14:2887-2895.Assessment of BRAF V600E status in colorectal carcinomaJournal of Molecular DiagnosticsJournal of Molecular Diagnostics. 18:676-687.Journal of Molecular DiagnosticsArchives of Pathology and Laboratory MedicineTemplate for reporting results of biomarker testing of specimens from patients with diffuse large B-cell lymphoma, not otherwise specified. Archives of Pathology and Laboratory Medicine. 140:1225-1227.Template for reporting results of biomarker testing of specimens from patients with diffuse large B-cell lymphoma, not otherwise specifiedFrontiers in OncologyExtramedullary acute myeloid leukemia. Frontiers in Oncology. 4 JUN.Extramedullary acute myeloid leukemiaArchives of Pathology and Laboratory MedicineTemplate for reporting results of biomarker testing of specimens from patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Archives of Pathology and Laboratory Medicine. 140:1228-1230.Template for reporting results of biomarker testing of specimens from patients with chronic lymphocytic leukemia/small lymphocytic lymphomaAmerican Journal of Clinical PathologyMyeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic features. American Journal of Clinical Pathology. 145:418-427.Myeloproliferative neoplasms with calreticulin mutations exhibit distinctive morphologic featuresCancer geneticsWhole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Cancer genetics. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)OncotargetClinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 6:20099-20110.Clinical next generation sequencing to identify actionable aberrations in a phase I programCancer geneticsAcute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer genetics. 208:571-574.Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutationLeukemia and LymphomaMyelodysplastic syndromes following therapy with hypomethylating agents (HMAs). Leukemia and Lymphoma. 57:812-819.Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs)OncotargetClinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents. Oncotarget. 7:14172-14187.Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agentsHaematologicaPre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia. Haematologica. 102:110-117.Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemiaAmerican Journal of HematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology. 91:E478-E479.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemiaThe Lancet OncologyPreleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms. The Lancet Oncology. 18:100-111.Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasmsAmerican Journal of Clinical PathologyIdentification of factors affecting the success of next-generation sequencing testing in solid tumors. American Journal of Clinical Pathology. 145:222-237.Identification of factors affecting the success of next-generation sequencing testing in solid tumors28395087Ballester LY, Fuller GN, Powell SZ, Sulman EP, Patel KP, Luthra R, Routbort MJJournal of neuropathology and experimental neurologyRetrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. J Neuropathol Exp Neurol. 2017 03 01; 76(3):179-188.J Neuropathol Exp Neurol2017-03-01T00:00:002017Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors.Authorship 88842420Authorship 8898035D009154Physiology2017151480.239304MutationD015470Disorders52568840.242968Leukemia, Myeloid, AcuteD009196Disorders1397660.579171Myeloproliferative DisordersAuthorship 8978482Authorship 9035434Authorship 9040148Authorship 9040428Authorship 9041154Authorship 9043174Authorship 9047084Authorship 90503511Authorship 9055317Authorship 9058472Authorship 90609910Authorship 9063399Authorship 9068962Authorship 90697711Authorship 9070012Authorship 9074718Authorship 9088683Authorship 9103974Authorship 9104637Authorship 9107853Authorship 9113303Authorship 91206211Authorship 91252713Authorship 9128802Authorship 9129302Authorship 9130355Authorship 91355218Authorship 91367911Authorship 9138233Authorship 9139383Authorship 9139393Authorship 9153483Authorship 9163896Authorship 9166128Authorship 9171743Authorship 91882012Authorship 9191094Authorship 9199056Authorship 9210554Authorship 9212016Authorship 9214174Authorship 92192010Authorship 9224625Authorship 9225135Authorship 9231827Authorship 9233444Authorship 9233647Authorship 92397411Authorship 9243217Authorship 9252458Authorship 9260093Authorship 9261638Authorship 92637111Authorship 9275562Authorship 9279464Authorship 92799013Authorship 92834327Authorship 9290675Authorship 92922514Authorship 9296342Authorship 9297866Authorship 9300517Authorship 93049010Authorship 93084818Authorship 9326111Authorship 9337618Authorship 93474623Authorship 9348893Authorship 9368433Authorship 9375779Authorship 93777913Authorship 939232318315481Ost MC, Patel KP, Rastinehad AR, Chu PY, Anderson AE, Smith AD, Lee BRJournal of endourologyPneumoperitoneum with carbon dioxide inhibits macrophage tumor necrosis factor-alpha secretion: source of transitional-cell carcinoma port-site metastasis, with prophylactic irrigation strategies to decrease laparoscopic oncologic risks. J Endourol. 2008 Jan; 22(1):105-12.J Endourol2008-01-01T00:00:002008Pneumoperitoneum with carbon dioxide inhibits macrophage tumor necrosis factor-alpha secretion: source of transitional-cell carcinoma port-site metastasis, with prophylactic irrigation strategies to decrease laparoscopic oncologic risks.24982452Jain P, Ok CY, Konoplev S, Patel KP, Jorgensen J, Estrov Z, Luthra R, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyRelapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity? J Clin Oncol. 2016 Mar 01; 34(7):e57-60.J Clin Oncol2014-06-30T00:00:002014Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?26293512Peng J, Hasserjian RP, Tang G, Patel KP, Goswami M, Jabbour EJ, Garcia-Manero G, Medeiros LJ, Wang SALeukemia & lymphomaMyelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response. Leuk Lymphoma. 2016; 57(4):812-9.Leuk Lymphoma2016-03-04T00:00:002016Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.26700872Jain P, Verstovsek S, Wang W, Loghavi S, Torres HA, Estrov Z, Patel KP, Pemmaraju NLeukemia & lymphomaDNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1969-73.Leuk Lymphoma2015-12-24T00:00:002015DNMT3A, TET2, and JAK2 mutations in polycythemia vera following long-term remission of secondary acute myeloid leukemia.26765348Kanagal-Shamanna R, Singh RR, Routbort MJ, Patel KP, Medeiros LJ, Luthra RExpert review of molecular diagnosticsPrinciples of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory. Expert Rev Mol Diagn. 2016; 16(4):461-72.Expert Rev Mol Diagn2016-02-15T00:00:002016Principles of analytical validation of next-generation sequencing based mutational analysis for hematologic neoplasms in a CLIA-certified laboratory.26843047Mehrotra M, Patel KPMethods in molecular biology (Clifton, N.J.)High-Resolution Melt Curve Analysis in Cancer Mutation Screen. Methods Mol Biol. 2016; 1392:63-9.Methods Mol Biol2016-01-01T00:00:002016High-Resolution Melt Curve Analysis in Cancer Mutation Screen.26883102Kanagal-Shamanna R, Luthra R, Yin CC, Patel KP, Takahashi K, Lu X, Lee J, Zhao C, Stingo F, Zuo Z, Routbort MJ, Singh RR, Fox P, Ravandi F, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CEOncotargetMyeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS. Oncotarget. 2016 Mar 22; 7(12):14251-8.Oncotarget2016-03-22T00:00:002016Myeloid neoplasms with isolated isochromosome 17q demonstrate a high frequency of mutations in SETBP1, SRSF2, ASXL1 and NRAS.27081876Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C, Members of the Cancer Biomarker Reporting Committee, College of American PathologistsArchives of pathology & laboratory medicineTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified. Arch Pathol Lab Med. 2016 11; 140(11):1225-1227.Arch Pathol Lab Med2016-04-15T00:00:002016Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.27081879Duncavage E, Advani RH, Agosti S, Foulis P, Gibson C, Kang L, Khoury JD, Medeiros LJ, Ohgami RS, O'Malley DP, Patel KP, Rosenbaum JN, Wilson C, Members of the Cancer Biomarker Reporting Committee, College of American PathologistsArchives of pathology & laboratory medicineTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Arch Pathol Lab Med. 2016 Nov; 140(11):1228-1230.Arch Pathol Lab Med2016-04-15T00:00:002016Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.26729897Jain P, Kantarjian H, Patel KP, Gonzalez GN, Luthra R, Kanagal Shamanna R, Sasaki K, Jabbour E, Romo CG, Kadia TM, Pemmaraju N, Daver N, Borthakur G, Estrov Z, Ravandi F, O'Brien S, Cortes JBloodImpact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. Blood. 2016 Mar 10; 127(10):1269-75.Blood2016-01-04T00:00:002016Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors.26872013Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RNThe American journal of surgical pathologyPrognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol. 2016 May; 40(5):676-88.Am J Surg Pathol2016-05-01T00:00:002016Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases.26653363Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JLArchives of pathology & laboratory medicineTemplate for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med. 2016 Jul; 140(7):672-4.Arch Pathol Lab Med2015-12-11T00:00:002015Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)).26653364Kelley TW, Arber DA, Gibson C, Jones D, Khoury JD, Medeiros BC, O'Malley DP, Patel KP, Pilichowska M, Vasef MA, Wallentine J, Zehnder JLArchives of pathology & laboratory medicineTemplate for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.Arch Pathol Lab Med2015-12-11T00:00:002015Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms.27283170Loghavi S, Routbort MJ, Patel KP, Luthra R, Wang WL, Broaddus RR, Davies MA, Lazar AJJournal of the National Comprehensive Cancer Network : JNCCNHow Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments? J Natl Compr Canc Netw. 2016 06; 14(6):787-92.J Natl Compr Canc Netw2016-06-01T00:00:002016How Do We Make Clinical Molecular Testing for Cancer Standard of Care for Pathology Departments?27443511Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RPModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncAcute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016 10; 29(10):1221-31.Mod Pathol2016-07-15T00:00:002016Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.27124905Goswami RS, Luthra R, Singh RR, Patel KP, Routbort MJ, Aldape KD, Yao H, Dang HD, Barkoh BA, Manekia J, Medeiros LJ, Roy-Chowdhuri S, Stewart J, Broaddus RR, Chen HAmerican journal of clinical pathologyIdentification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors. Am J Clin Pathol. 2016 Feb; 145(2):222-37.Am J Clin Pathol2016-02-12T00:00:002016Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.27124925Loghavi S, Bueso-Ramos CE, Kanagal-Shamanna R, Ok CY, Salim AA, Routbort MJ, Mehrotra M, Verstovsek S, Medeiros LJ, Luthra R, Patel KPAmerican journal of clinical pathologyMyeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features. Am J Clin Pathol. 2016 03; 145(3):418-27.Am J Clin Pathol2016-03-01T00:00:002016Myeloproliferative Neoplasms With Calreticulin Mutations Exhibit Distinctive Morphologic Features.27134073Hong M, Hao S, Patel KP, Kantarjian HM, Garcia-Manero G, Yin CC, Medeiros LJ, Lin P, Lu XCancer geneticsWhole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup. Cancer Genet. 2016 05; 209(5):205-14.Cancer Genet2016-04-06T00:00:002016Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.27268124Ballester LY, Loghavi S, Kanagal-Shamanna R, Barkoh BA, Lin P, Medeiros LJ, Luthra R, Patel KPClinical lymphoma, myeloma & leukemiaClinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2016 07; 16(7):395-403.e1.Clin Lymphoma Myeloma Leuk2016-05-05T00:00:002016Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.26980021Alayed K, Medeiros LJ, Patel KP, Zuo Z, Li S, Verma S, Galbincea J, Cason RC, Luthra R, Yin CCHuman pathologyBRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases. Hum Pathol. 2016 06; 52:61-7.Hum Pathol2016-02-01T00:00:002016BRAF and MAP2K1 mutations in Langerhans cell histiocytosis: a study of 50 cases.27392636Singh RR, Mehrotra M, Chen H, Almohammedsalim AA, Sahin A, Bosamra A, Patel KP, Routbort MJ, Lu X, Ronald A, Mishra BM, Virani S, Medeiros LJ, Luthra RThe Journal of molecular diagnostics : JMDComprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array. J Mol Diagn. 2016 09; 18(5):676-687.J Mol Diagn2016-07-05T00:00:002016Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array.27468087Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov ZAmerican journal of hematologyClinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 11; 91(11):E478-E479.Am J Hematol2016-08-22T00:00:002016Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia.27895713Gu J, Reynolds A, Fang L, DeGraffenreid C, Sterns K, Patel KP, Medeiros LJ, Lin P, Lu XMolecular cytogeneticsCoexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases. Mol Cytogenet. 2016; 9:84.Mol Cytogenet2016-11-21T00:00:002016Coexistence of iAMP21 and ETV6-RUNX1 fusion in an adolescent with B cell acute lymphoblastic leukemia: literature review of six additional cases.28084334Pina-Oviedo S, Medeiros LJ, Li S, Khoury JD, Patel KP, Alayed K, Cason RC, Bowman CJ, Yin CCModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncLangerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. Mod Pathol. 2017 05; 30(5):734-744.Mod Pathol2017-01-13T00:00:002017Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations.28125801Chen H, Singh RR, Lu X, Huo L, Yao H, Aldape K, Abraham R, Virani S, Mehrotra M, Mishra BM, Bousamra A, Albarracin C, Wu Y, Roy-Chowdhuri S, Kanagal-Shamanna R, Routbort MJ, Medeiros LJ, Patel KP, Broaddus R, Sahin A, Luthra ROncotargetGenome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray. Oncotarget. 2017 02 14; 8(7):10845-10857.Oncotarget2017-02-14T00:00:002017Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.28267766Mehrvarz Sarshekeh A, Advani S, Overman MJ, Manyam G, Kee BK, Fogelman DR, Dasari A, Raghav K, Vilar E, Manuel S, Shureiqi I, Wolff RA, Patel KP, Luthra R, Shaw K, Eng C, Maru DM, Routbort MJ, Meric-Bernstam F, Kopetz SPloS oneAssociation of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. PLoS One. 2017; 12(3):e0173345.PLoS One2017-03-07T00:00:002017Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer.28188106Lih CJ, Harrington RD, Sims DJ, Harper KN, Bouk CH, Datta V, Yau J, Singh RR, Routbort MJ, Luthra R, Patel KP, Mantha GS, Krishnamurthy S, Ronski K, Walther Z, Finberg KE, Canosa S, Robinson H, Raymond A, Le LP, McShane LM, Polley EC, Conley BA, Doroshow JH, Iafrate AJ, Sklar JL, Hamilton SR, Williams PMThe Journal of molecular diagnostics : JMDAnalytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial. J Mol Diagn. 2017 03; 19(2):313-327.J Mol Diagn2017-02-07T00:00:002017Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.28017569Luthra R, Patel KP, Routbort MJ, Broaddus RR, Yau J, Simien C, Chen W, Hatfield DZ, Medeiros LJ, Singh RRThe Journal of molecular diagnostics : JMDA Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors. J Mol Diagn. 2017 03; 19(2):255-264.J Mol Diagn2016-12-23T00:00:002016A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.28084342Roy-Chowdhuri S, Chen H, Singh RR, Krishnamurthy S, Patel KP, Routbort MJ, Manekia J, Barkoh BA, Yao H, Sabir S, Broaddus RR, Medeiros LJ, Staerkel G, Stewart J, Luthra RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncConcurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies. Mod Pathol. 2017 04; 30(4):499-508.Mod Pathol2017-01-13T00:00:002017Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies.28291640Masarova L, Patel KP, Newberry KJ, Cortes J, Borthakur G, Konopleva M, Estrov Z, Kantarjian H, Verstovsek SThe Lancet. HaematologyPegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial. Lancet Haematol. 2017 Apr; 4(4):e165-e175.Lancet Haematol2017-03-11T00:00:002017Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial.28382648Jain P, Milgrom SA, Patel KP, Nastoupil L, Fayad L, Wang M, Pinnix CC, Dabaja BS, Smith GL, Yu J, Hu S, Bueso Ramos CE, Kanagal-Shamanna R, Medeiros LJ, Oki Y, Fowler NBritish journal of haematologyCharacteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017 08; 178(3):403-412.Br J Haematol2017-04-06T00:00:002017Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.28494520Wang W, Routbort MJ, Ok CY, Patel KP, Sun Y, Kanagal-Shamanna R, Medeiros LJ, Wang SAAmerican journal of hematologyCharacterization of TP53 mutations in clonal cytopenia of undetermined significance. Am J Hematol. 2017 Aug; 92(8):E175-E177.Am J Hematol2017-06-09T00:00:002017Characterization of TP53 mutations in clonal cytopenia of undetermined significance.28608976Kanagal-Shamanna R, Jain P, Takahashi K, Short NJ, Tang G, Issa GC, Ravandi F, Garcia-Manero G, Yin CC, Luthra R, Patel KP, Khoury JD, Montalban-Bravo G, Sasaki K, Kadia TM, Borthakur G, Konopleva M, Jain N, Garris R, Pierce S, Wierda W, Estrov Z, Cortes J, O'Brien S, Kantarjian HM, Jabbour ECancerTP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens. Cancer. 2017 Oct 01; 123(19):3717-3724.Cancer2017-06-13T00:00:002017TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.28599188Jain P, Wang S, Patel KP, Sarwari N, Cortes J, Kantarjian H, Verstovsek SLeukemia researchMast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome. Leuk Res. 2017 08; 59:105-109.Leuk Res2017-06-01T00:00:002017Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome.28664935Garces S, Medeiros LJ, Patel KP, Li S, Pina-Oviedo S, Li J, Garces JC, Khoury JD, Yin CCModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncMutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease. Mod Pathol. 2017 10; 30(10):1367-1377.Mod Pathol2017-06-30T00:00:002017Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease.28664939Onaindia A, Medeiros LJ, Patel KPModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms. Mod Pathol. 2017 10; 30(10):1338-1366.Mod Pathol2017-06-30T00:00:002017Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.28248813Agbay RL, Torres-Cabala CA, Patel KP, Merril ED, Duvic M, Quesada A, Prieto VG, Aung PP, Loghavi S, Young KH, Hu S, Ferrufino-Schmidt MC, Tetzlaff M, Li S, Medeiros LJ, Miranda RNThe American journal of surgical pathologyImmunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens. Am J Surg Pathol. 2017 Apr; 41(4):431-445.Am J Surg Pathol2017-04-01T00:00:002017Immunophenotypic Shifts in Primary Cutaneous ?d T-Cell Lymphoma Suggest Antigenic Modulation: A Study of Sequential Biopsy Specimens.28449808Mehrotra M, Luthra R, Abraham R, Mishra BM, Virani S, Chen H, Routbort MJ, Patel KP, Medeiros LJ, Singh RRCancer geneticsValidation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples. Cancer Genet. 2017 04; 212-213:24-31.Cancer Genet2017-03-20T00:00:002017Validation of quantitative PCR-based assays for detection of gene copy number aberrations in formalin-fixed, paraffin embedded solid tumor samples.28506684Mehrotra M, Singh RR, Chen W, Huang RSP, Almohammedsalim AA, Barkoh BA, Simien CM, Hernandez M, Behrens C, Patel KP, Routbort MJ, Broaddus RR, Medeiros LJ, Wistuba II, Kopetz S, Luthra RThe Journal of molecular diagnostics : JMDStudy of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid. J Mol Diagn. 2017 07; 19(4):514-524.J Mol Diagn2017-05-12T00:00:002017Study of Preanalytic and Analytic Variables for Clinical Next-Generation Sequencing of Circulating Cell-Free Nucleic Acid.28682832Badar T, Luthra R, Kantarjian H, Jabbour E, Borthakur G, Garcia-Manero G, Huang X, Singh R, Alvarez B, Austermiller B, Morrison TB, Patel KP, Cortes JApplied immunohistochemistry & molecular morphology : AIMMNew Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia. Appl Immunohistochem Mol Morphol. 2019 01; 27(1):33-39.Appl Immunohistochem Mol Morphol2019-01-01T00:00:002019New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia.28933735Khan M, Cortes J, Kadia T, Naqvi K, Brandt M, Pierce S, Patel KP, Borthakur G, Ravandi F, Konopleva M, Kornblau S, Kantarjian H, Bhalla K, DiNardo CDInternational journal of molecular sciencesClinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia. Int J Mol Sci. 2017 Jul 26; 18(8).Int J Mol Sci2017-07-26T00:00:002017Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.28926144Wang W, Routbort MJ, Tang Z, Ok CY, Patel KP, Daver N, Garcia-Manero G, Medeiros LJ, Wang SAEuropean journal of haematologyCharacterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype. Eur J Haematol. 2017 Dec; 99(6):536-543.Eur J Haematol2017-10-20T00:00:002017Characterization of TP53 mutations in low-grade myelodysplastic syndromes and myelodysplastic syndromes with a non-complex karyotype.29119847Strati P, Tang G, Duose DY, Mallampati S, Luthra R, Patel KP, Hussaini M, Mirza AS, Komrokji RS, Oh S, Mascarenhas J, Najfeld V, Subbiah V, Kantarjian H, Garcia-Manero G, Verstovsek S, Daver NLeukemia & lymphomaMyeloid/lymphoid neoplasms with FGFR1 rearrangement. Leuk Lymphoma. 2018 07; 59(7):1672-1676.Leuk Lymphoma2017-11-09T00:00:002017Myeloid/lymphoid neoplasms with FGFR1 rearrangement.28760304Patel U, Luthra R, Medeiros LJ, Patel KPClinical lymphoma, myeloma & leukemiaDiagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms. Clin Lymphoma Myeloma Leuk. 2017 07; 17S:S62-S74.Clin Lymphoma Myeloma Leuk2017-07-01T00:00:002017Diagnostic, Prognostic, and Predictive Utility of Recurrent Somatic Mutations in Myeloid Neoplasms.28767674Mehrotra M, Duose DY, Singh RR, Barkoh BA, Manekia J, Harmon MA, Patel KP, Routbort MJ, Medeiros LJ, Wistuba II, Luthra RPloS oneVersatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory. PLoS One. 2017; 12(8):e0181968.PLoS One2017-08-02T00:00:002017Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.28885734Loghavi S, Curry JL, Garcia-Manero G, Patel KP, Xu J, Khoury JD, Torres-Cabala CA, Nagarajan P, Aung PP, Gibson BR, Goodwin BP, Kelly BC, Korivi BR, Medeiros LJ, Prieto VG, Kantarjian HM, Bueso-Ramos CE, Tetzlaff MTJournal of cutaneous pathologyChronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia. J Cutan Pathol. 2017 Dec; 44(12):1075-1079.J Cutan Pathol2017-09-27T00:00:002017Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.29695638Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MDMolecular cancer therapeuticsMolecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy. Mol Cancer Ther. 2018 07; 17(7):1575-1584.Mol Cancer Ther2018-04-25T00:00:002018Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing Tumors Beyond Diagnosis for Targeted Therapy.29385279Kurt H, Jorgensen JL, Amin HM, Patel KP, Wang SA, Lin P, Kanagal-Shamanna R, Loghavi S, Thakral B, Khogeer HA, Jabbour EJ, Li S, Yin CC, Medeiros LJ, Khoury JDEuropean journal of haematologyChronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.Eur J Haematol2018-03-09T00:00:002018Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools.29448058Shah MV, Jorgensen JL, Saliba RM, Wang SA, Alousi AM, Andersson BS, Bashir Q, Ciurea SO, Kebriaei P, Marin D, Patel KP, Popat UR, Rezvani K, Rondon G, Shpall EJ, Champlin RE, Oran BBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationEarly Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.Biol Blood Marrow Transplant2018-02-12T00:00:002018Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia.29535804Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra ROncotargetDetection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors. Oncotarget. 2018 02 13; 9(12):10259-10271.Oncotarget2017-10-24T00:00:002017Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.29682723DiNardo CD, Routbort MJ, Bannon SA, Benton CB, Takahashi K, Kornblau SM, Luthra R, Kanagal-Shamanna R, Medeiros LJ, Garcia-Manero G, M Kantarjian H, Futreal PA, Meric-Bernstam F, Patel KPCancerImproving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels. Cancer. 2018 07 01; 124(13):2704-2713.Cancer2018-04-06T00:00:002018Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels.29358183Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli ABloodClinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood. 2018 04 19; 131(16):1820-1832.Blood2018-01-22T00:00:002018Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide.29265180Shah MV, Patel KP, Luthra R, Kanagal-Shamanna R, Mehrotra M, Bachegowda LS, Champlin RE, Verstovsek S, Popat URBritish journal of haematologySensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation. Br J Haematol. 2018 12; 183(5):831-835.Br J Haematol2017-12-19T00:00:002017Sensitive PCR-based monitoring and early detection of relapsed JAK2 V617F myelofibrosis following transplantation.29409729Simkins A, Maiti A, Short NJ, Jain N, Popat U, Patel KP, Oo THHematology/oncology and stem cell therapyAcquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2019 Jun; 12(2):115-118.Hematol Oncol Stem Cell Ther2018-01-31T00:00:002018Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation.29490944Ishizawa J, Nakamaru K, Seki T, Tazaki K, Kojima K, Chachad D, Zhao R, Heese L, Ma W, Ma MCJ, DiNardo C, Pierce S, Patel KP, Tse A, Davis RE, Rao A, Andreeff MCancer researchPredictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res. 2018 05 15; 78(10):2721-2731.Cancer Res2018-02-28T00:00:002018Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition.29492206Quesada AE, Hu Z, Routbort MJ, Patel KP, Luthra R, Loghavi S, Zuo Z, Yin CC, Kanagal-Shamanna R, Wang SA, Jorgensen JL, Medeiros LJ, Ok CYOncotargetMixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing. Oncotarget. 2018 Feb 02; 9(9):8441-8449.Oncotarget2018-01-03T00:00:002018Mixed phenotype acute leukemia contains heterogeneous genetic mutations by next-generation sequencing.29635257Kurt H, Bueso-Ramos CE, Khoury JD, Routbort MJ, Kanagal-Shamanna R, Patel UV, Jorgensen JL, Wang SA, Ravandi F, DiNardo C, Luthra R, Medeiros LJ, Patel KPThe American journal of surgical pathologyCharacterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms. Am J Surg Pathol. 2018 05; 42(5):569-577.Am J Surg Pathol2018-05-01T00:00:002018Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.29702001Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi KJournal of clinical oncology : official journal of the American Society of Clinical OncologyClearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 06 20; 36(18):1788-1797.J Clin Oncol2018-04-27T00:00:002018Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.30005850Chen H, Luthra R, Patel KP, Routbort M, Rashid A, Roy-Chowdhuri S, Lazar A, Broaddus R, Manekia J, Singh RR, Yemelyanova ACancer geneticsChallenges in next generation sequencing analysis of somatic mutations in transplant patients. Cancer Genet. 2018 10; 226-227:17-22.Cancer Genet2018-05-10T00:00:002018Challenges in next generation sequencing analysis of somatic mutations in transplant patients.30409776Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM, Ning J, Pemmaraju N, DiNardo CD, Andreeff M, Pierce SA, Gordon T, Kornblau SM, Flores W, Alhamal Z, Bueso-Ramos C, Jorgensen JL, Patel KP, Blando J, Allison JP, Sharma P, Kantarjian HCancer discoveryEfficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. Cancer Discov. 2019 03; 9(3):370-383.Cancer Discov2018-11-08T00:00:002018Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study.29884905Boddu P, Gurguis C, Sanford D, Cortes J, Akosile M, Ravandi F, Garcia-Manero G, Patel KP, Kadia T, Brandt M, Maduike R, Kantarjian H, Borthakur GLeukemiaResponse kinetics and factors predicting survival in core-binding factor leukemia. Leukemia. 2018 12; 32(12):2698-2701.Leukemia2018-06-08T00:00:002018Response kinetics and factors predicting survival in core-binding factor leukemia.30171025Ok CY, Loghavi S, Sui D, Wei P, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Tang G, Tang Z, Jorgensen JL, Luthra R, Ravandi F, Kantarjian HM, DiNardo CD, Medeiros LJ, Wang SA, Patel KPHaematologicaPersistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia. Haematologica. 2019 02; 104(2):305-311.Haematologica2018-08-31T00:00:002018Persistent IDH1/2 mutations in remission can predict relapse in patients with acute myeloid leukemia.30323237Garces S, Yin CC, Patel KP, Khoury JD, Manning JT, Li S, Xu J, Pina-Oviedo S, Johnson MR, Gonz?lez S, Molg? M, Ruiz-Cordero R, Medeiros LJModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncFocal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation. Mod Pathol. 2019 01; 32(1):16-26.Mod Pathol2018-10-15T00:00:002018Focal Rosai-Dorfman disease coexisting with lymphoma in the same anatomic site: a localized histiocytic proliferation associated with MAPK/ERK pathway activation.29769261Ciurea SO, Chilkulwar A, Saliba RM, Chen J, Rondon G, Patel KP, Khogeer H, Shah AR, Randolph BV, Perez JMR, Popat U, Hosing CM, Bashir Q, Mehta R, Al-Atrash G, Im J, Khouri IF, Kebriaei P, Champlin REBloodPrognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018 06 28; 131(26):2989-2992.Blood2018-05-16T00:00:002018Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations.29951914Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek SAnnals of hematologyThe co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol. 2018 Nov; 97(11):2071-2080.Ann Hematol2018-06-27T00:00:002018The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.29955146Angelova EA, Medeiros LJ, Wang W, Muzzafar T, Lu X, Khoury JD, Ravandi F, Patel KP, Hu Z, Kanagal-Shamanna RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience. Mod Pathol. 2018 11; 31(11):1717-1732.Mod Pathol2018-06-28T00:00:002018Clinicopathologic and molecular features in hairy cell leukemia-variant: single institutional experience.30086334Garces S, Khoury JD, Kanagal-Shamanna R, Salem A, Wang SA, Ok CY, Hu S, Patel KP, Routbort MJ, Luthra R, Tang G, Schlette EJ, Bueso-Ramos CE, Medeiros LJ, Loghavi SHuman pathologyChronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. Hum Pathol. 2018 12; 82:215-231.Hum Pathol2018-08-04T00:00:002018Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption.30222780Montes-Moreno S, Routbort MJ, Lohman EJ, Barkoh BA, Kanagal-Shamanna R, Bueso-Ramos CE, Singh RR, Medeiros LJ, Luthra R, Patel KPPloS oneClinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era. PLoS One. 2018; 13(9):e0204218.PLoS One2018-09-17T00:00:002018Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era.30508305Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJCancerTargeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation. Cancer. 2019 02 15; 125(4):559-574.Cancer2018-12-03T00:00:002018Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.30577887Patel KP, Ruiz-Cordero R, Chen W, Routbort MJ, Floyd K, Rodriguez S, Galbincea J, Barkoh BA, Hatfield D, Khogeer H, Kanagal-Shamanna R, Yin CC, Zuo Z, Loghavi S, Ok CY, DiNardo CD, Luthra R, Medeiros LJThe Journal of molecular diagnostics : JMDUltra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection. J Mol Diagn. 2019 01; 21(1):89-98.J Mol Diagn2019-01-01T00:00:002019Ultra-Rapid Reporting of GENomic Targets (URGENTseq): Clinical Next-Generation Sequencing Results within 48?Hours of Sample Collection.30709875Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CDCold Spring Harbor molecular case studiesHematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud. 2019 02; 5(1).Cold Spring Harb Mol Case Stud2019-02-01T00:00:002019Hematologic malignancies and Li-Fraumeni syndrome.30463063Swaminathan M, Patel KP, Huynh-Lu J, Tang G, Zuo Z, Miranda R, Verstovsek SActa haematologicaUnique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript. Acta Haematol. 2019; 141(1):23-27.Acta Haematol2018-11-21T00:00:002018Unique Case of Myeloproliferative Neoplasm with Two Rare Clonal Abnormalities: Rare JAK2 Exon 12 Mutation and Rare e14a3 (b3a3) BCR/ABL Fusion Transcript.D004252Procedures70322810.629479DNA Mutational AnalysisAuthorship 9414514Authorship 941760730838674Abbas HA, Ravandi F, Loghavi S, Patel KP, Borthakur G, Kadia TM, Jabbour E, Takahashi K, Cortes J, Issa GC, Konopleva M, Kantarjian HM, Short NJAmerican journal of hematologyNPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia. Am J Hematol. 2019 06; 94(6):E158-E160.Am J Hematol2019-03-18T00:00:002019NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.30796023Pemmaraju N, Kantarjian H, Nastoupil L, Dupuis M, Zhou L, Pierce S, Patel KP, Masarova L, Cortes J, Verstovsek SBloodCharacteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019 05 23; 133(21):2348-2351.Blood2019-02-22T00:00:002019Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy.30924136Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WGBritish journal of haematologyRoutine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. Br J Haematol. 2019 06; 185(5):852-864.Br J Haematol2019-03-28T00:00:002019Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments.Authorship 9438224Authorship 9441221730242087Bose P, Nazha A, Komrokji RS, Patel KP, Pierce SA, Al-Ali N, Sochacki A, Shaver A, Ma W, Su X, Daver NG, DiNardo CD, Garcia-Manero G, Loghavi S, Bueso-Ramos C, Kantarjian HM, Sekeres MA, Savona MR, Maciejewski JP, Verstovsek SBloodMutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable. Blood. 2018 11 08; 132(19):2100-2103.Blood2018-09-21T00:00:002018Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.30185431Masarova L, Verstovsek S, Hidalgo-Lopez JE, Pemmaraju N, Bose P, Estrov Z, Jabbour EJ, Ravandi-Kashani F, Takahashi K, Cortes JE, Ning J, Ohanian M, Alvarado Y, Zhou L, Pierce S, Gergis R, Patel KP, Luthra R, Kadia TM, DiNardo CD, Borthakur G, Bhalla K, Garcia-Manero G, Bueso-Ramos CE, Kantarjian HM, Daver NBloodA phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis. Blood. 2018 10 18; 132(16):1664-1674.Blood2018-09-05T00:00:002018A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.Authorship 94450319Authorship 944571230963592Quesada AE, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Khoury JD, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, Bannon SA, Benton CB, Garcia-Manero G, Kantarjian H, Luthra R, Medeiros LJ, Patel KPAmerican journal of hematologyDDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.Am J Hematol2019-05-07T00:00:002019DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.D059014Procedures70222850.507467High-Throughput Nucleotide SequencingAuthorship 9474644Authorship 947937331109591Tang Z, Tang G, Hu S, Patel KP, Yin CC, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Medeiros LJCancer geneticsDeciphering the complexities of MECOM rearrangement-driven chromosomal aberrations. Cancer Genet. 2019 04; 233-234:21-31.Cancer Genet2019-03-11T00:00:002019Deciphering the complexities of MECOM rearrangement-driven chromosomal aberrations.31132650Sakhdari A, Ok CY, Patel KP, Kanagal-Shamanna R, Yin CC, Zuo Z, Hu S, Routbort MJ, Luthra R, Medeiros LJ, Khoury JD, Loghavi SAnnals of diagnostic pathologyTP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant. Ann Diagn Pathol. 2019 Aug; 41:38-42.Ann Diagn Pathol2019-05-16T00:00:002019TP53 mutations are common in mantle cell lymphoma, including the indolent leukemic non-nodal variant.Authorship 949067431193989Tang Z, Tang G, Hu S, Patel KP, Cameron Yin C, Wang W, Lin P, Toruner GA, Ok CY, Gu J, Lu X, Khoury JD, Jeffrey Medeiros LData in briefData on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies. Data Brief. 2019 Jun; 24:104025.Data Brief2019-05-23T00:00:002019Data on MECOM rearrangement-driven chromosomal aberrations in myeloid malignancies.Authorship 950705231243771Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WGBritish journal of haematologyAssociation of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. Br J Haematol. 2019 11; 187(3):307-318.Br J Haematol2019-06-26T00:00:002019Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients.Authorship 9517319Authorship 951785531279181Jain P, Gu J, Kanagal-Shamanna R, Tang Z, Patel KP, Yao H, Fang L, Bao HY, Liu CH, Lin P, Medeiros LJ, Lu XLeukemia researchClinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens. Leuk Res. 2019 09; 84:106176.Leuk Res2019-06-27T00:00:002019Clinical implications of cytogenetic heterogeneity in Philadelphia chromosome positive (Ph+) adult B cell acute lymphoblastic leukemia following tyrosine kinase inhibitors and chemotherapy regimens.31296578Srour SA, Olson A, Ciurea SO, Desai P, Bashir Q, Oran B, Bose P, Mehta R, Patel KP, Pemmaraju N, Daver N, Verstovsek S, Champlin RE, Popat URHaematologicaMixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation. Haematologica. 2021 07 01; 106(7):1988-1990.Haematologica2021-07-01T00:00:002021Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.Authorship 953602631400013Abou Dalle I, Kantarjian H, Bannon SA, Kanagal-Shamanna R, Routbort M, Patel KP, Hu S, Bhalla K, Garcia-Manero G, DiNardo CDAmerican journal of hematologySuccessful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020 02; 95(2):227-229.Am J Hematol2019-08-29T00:00:002019Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation.Authorship 955508631518645Kongtim P, Hasan O, Perez JMR, Varma A, Wang SA, Patel KP, Chen J, Rondon G, Srour S, Bashir Q, Qazilbash M, Mehta R, Shpall EJ, Alousi A, Khouri I, Kebriaei P, Popat U, Champlin RR, Ciurea SOBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationNovel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 01; 26(1):197-203.Biol Blood Marrow Transplant2019-09-10T00:00:002019Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation.Authorship 956081631557598Chen Z, Wang SA, Goswami M, Tang G, Routbort MJ, Patel KP, Luthra R, Medeiros LJ, Ok CYLeukemia researchComparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leuk Res. 2019 11; 86:106227.Leuk Res2019-09-17T00:00:002019Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.Authorship 9621531131804006Sakhdari A, Thakral B, Loghavi S, Kanagal-Shamanna R, Yin CC, Zuo Z, Routbort MJ, Luthra R, Medeiros LJ, Wang SA, Patel KP, Ok CYCancer medicineRAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.Cancer Med2019-12-05T00:00:002019RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.Authorship 975123431896812Garces S, Yin CC, Miranda RN, Patel KP, Li S, Xu J, Thakral B, Poppiti RJ, Medina AM, Sriganeshan V, Castellano-S?nchez A, Khoury JD, Garces JC, Medeiros LJModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update. Mod Pathol. 2020 06; 33(6):1104-1121.Mod Pathol2020-01-02T00:00:002020Clinical, histopathologic, and immunoarchitectural features of dermatopathic lymphadenopathy: an update.Authorship 9767363Authorship 9767473Authorship 9768281532005111Ruiz-Cordero R, Ma J, Khanna A, Lyons G, Rinsurongkawong W, Bassett R, Guo M, Routbort MJ, Zhang J, Skoulidis F, Heymach J, Roarty EB, Tang Z, Medeiros LJ, Patel KP, Luthra R, Roy-Chowdhuri SBMC cancerSimplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer. 2020 Jan 31; 20(1):83.BMC Cancer2020-01-31T00:00:002020Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations.31999839Maiti A, Cortes JE, Patel KP, Masarova L, Borthakur G, Ravandi F, Verstovsek S, Ferrajoli A, Estrov Z, Garcia-Manero G, Kadia TM, Nogueras-Gonz?lez GM, Skinner J, Poku R, DellaSala S, Luthra R, Jabbour EJ, O'Brien S, Kantarjian HMCancerLong-term results of frontline dasatinib in chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1502-1511.Cancer2020-01-30T00:00:002020Long-term results of frontline dasatinib in chronic myeloid leukemia.31999850Masarova L, Cortes JE, Patel KP, O'Brien S, Nogueras-Gonzalez GM, Konopleva M, Verstovsek S, Garcia-Manero G, Ferrajoli A, Kadia TM, Ravandi-Kashani F, Borthakur G, DellaSala S, Estrov Z, Jabbour EJ, Kantarjian HMCancerLong-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia. Cancer. 2020 04 01; 126(7):1448-1459.Cancer2020-01-30T00:00:002020Long-term results of a phase 2 trial of nilotinib 400?mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia.Authorship 9775042032027746Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, Class CA, Chien KS, Sasaki K, Naqvi K, Alvarado Y, Kadia TM, Ravandi F, Daver N, Takahashi K, Jabbour E, Borthakur G, Pemmaraju N, Konopleva M, Soltysiak KA, Pierce SR, Bueso-Ramos CE, Patel KP, Kantarjian H, Garcia-Manero GBlood advancesGenomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020 02 11; 4(3):482-495.Blood Adv2020-02-11T00:00:002020Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes.Authorship 978552232101640Yalniz FF, Patel KP, Bashir Q, Marin D, Ahmed S, Alousi AM, Chen J, Ciurea SO, Rezvani K, Popat UR, Shpall EJ, Champlin RE, Oran BCancerSignificance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.Cancer2020-02-26T00:00:002020Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes.Authorship 9794172232191807Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang MLBlood advancesGenomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv. 2020 03 24; 4(6):1038-1050.Blood Adv2020-03-24T00:00:002020Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.Authorship 986314332238878Quesada AE, Montalban-Bravo G, Luthra R, Patel KP, Sasaki K, Bueso-Ramos CE, Khoury JD, Routbort MJ, Bassett R, Hidalgo-Lopez JE, Zhao C, Lin P, Loghavi S, Ok CY, Kadia T, DiNardo CD, Kantarjian H, Garcia-Manero G, Kanagal-Shamanna RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1. Mod Pathol. 2020 09; 33(9):1678-1689.Mod Pathol2020-04-01T00:00:002020Clinico-pathologic characteristics and outcomes of the World Health Organization (WHO) provisional entity de novo acute myeloid leukemia with mutated RUNX1.Authorship 9865621332251497Lachowiez CA, Loghavi S, Kadia TM, Daver N, Borthakur G, Pemmaraju N, Naqvi K, Alvarado Y, Yilmaz M, Short N, Ohanian M, Pierce SR, Patel KP, Qiao W, Ning J, Sasaki K, Takahashi K, Jabbour E, Andreeff M, Ravandi F, Kantarjian HM, Konopleva M, DiNardo CDBlood advancesOutcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens. Blood Adv. 2020 04 14; 4(7):1311-1320.Blood Adv2020-04-14T00:00:002020Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.Authorship 987908232324887Short NJ, Patel KP, Albitar M, Franquiz M, Luthra R, Kanagal-Shamanna R, Wang F, Assi R, Montalban-Bravo G, Matthews J, Ma W, Loghavi S, Takahashi K, Issa GC, Kornblau SM, Jabbour E, Garcia-Manero G, Kantarjian HM, Estrov Z, Ravandi FBlood advancesTargeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia. Blood Adv. 2020 04 28; 4(8):1670-1677.Blood Adv2020-04-28T00:00:002020Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia.32356320Short NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel KP, Konopleva M, Papageorgiou I, Pemmaraju N, Borthakur G, Ravandi F, DiNardo CD, Kadia TM, Kantarjian H, Lamba JK, Daver NAmerican journal of hematologyImpact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin. Am J Hematol. 2020 09; 95(9):E225-E228.Am J Hematol2020-05-23T00:00:002020Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.Authorship 9901044Authorship 991344332509784Gupta SK, Viswanatha DS, Patel KPFrontiers in cell and developmental biologyEvaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing. Front Cell Dev Biol. 2020; 8:357.Front Cell Dev Biol2020-05-19T00:00:002020Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing.Authorship 9921993Authorship 992758232561839Alfayez M, Issa GC, Patel KP, Wang F, Wang X, Short NJ, Cortes JE, Kadia T, Ravandi F, Pierce S, Assi R, Garcia-Manero G, DiNardo CD, Daver N, Pemmaraju N, Kantarjian H, Borthakur GLeukemiaThe Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia. Leukemia. 2021 03; 35(3):691-700.Leukemia2020-06-19T00:00:002020The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.32590457El Hussein S, Patel KP, Fang H, Thakral B, Loghavi S, Kanagal-Shamanna R, Konoplev S, Jabbour EJ, Medeiros LJ, Khoury JDThe American journal of surgical pathologyGenomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol. 2020 09; 44(9):1235-1243.Am J Surg Pathol2020-09-01T00:00:002020Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia.Authorship 994279332657180Alotaibi AS, Abdulrazzaq M, Patel KP, Ravandi F, Konoplev S, Bueso-Ramos C, Yin CC, Muzzafar T, Tang G, Futreal A, Jain N, Konopleva MY, Pemmaraju NLeukemia & lymphomaAcute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant. Leuk Lymphoma. 2020 12; 61(12):3018-3020.Leuk Lymphoma2020-07-11T00:00:002020Acute promyelocytic leukemia (APL) with an IRF2BP2-RARA fusion transcript: an aggressive APL variant.Authorship 9950224Authorship 995040932696696Thakral B, Daver N, Tang Z, Patel KP, Ok CY, Loghavi S, Khoury JD, Alotaibi AS, Konopleva M, Yilmaz M, Medeiros LJLeukemia & lymphomaClonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.Leuk Lymphoma2020-07-22T00:00:002020Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor.32697348Borthakur G, Zeng Z, Cortes JE, Chen HC, Huang X, Konopleva M, Ravandi F, Kadia T, Patel KP, Daver N, Kelly MA, McQueen T, Wang RY, Kantarjian H, Andreeff MAmerican journal of hematologyPhase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020 11; 95(11):1296-1303.Am J Hematol2020-08-19T00:00:002020Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.Authorship 9972911132804409Lachowiez C, Bannon S, Loghavi S, Wang F, Kanagal-Shamanna R, Mehta R, Daver N, Borthakur G, Pemmaraju N, Ravandi F, Patel KP, Garcia-Manero G, Takahashi K, Kantarjian H, Bhalla K, DiNardo CDAmerican journal of hematologyClonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations. Am J Hematol. 2020 11; 95(11):E313-E315.Am J Hematol2020-09-05T00:00:002020Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations.Authorship 998067432848129Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, Wei P, Khoury JD, You MJ, Loghavi S, Tang Z, Fang H, Thakral B, Medeiros LJ, Wang WBlood cancer journalClinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.Blood Cancer J2020-08-26T00:00:002020Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.Authorship 999337332914014Abou Dalle I, Bannon SA, Patel KP, Routbort MJ, Cortes JE, Ferrajoli A, Kontoyiannis DP, Wang SA, DiNardo CDJCO precision oncologyGermline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases. JCO Precis Oncol. 2019; 3.JCO Precis Oncol2019-03-04T00:00:002019Germline Genetic Predisposition to Myeloid Neoplasia From GATA2 Gene Mutations: Lessons Learned From Two Cases.Authorship 1000133732977233Lyapichev KA, Sakhdari A, Khoury JD, O'Malley DP, El Hussein S, Yin CC, Patel KP, Thakral B, Young KH, Medeiros LJ, Konoplev SAnnals of diagnostic pathologyLymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma. Ann Diagn Pathol. 2020 Dec; 49:151636.Ann Diagn Pathol2020-09-19T00:00:002020Lymphoid enhancer binding factor 1 (LEF1) expression is significantly higher in Hodgkin lymphoma associated with Richter syndrome relative to de novo classic Hodgkin lymphoma.Authorship 10021909Authorship 1002308933022638Gupta SK, Jain N, Tang G, Futreal A, Wang SA, Khoury JD, Yang RK, Fang H, Patel KP, Luthra R, Routbort M, Barkoh BA, Chen W, Mao X, Zhang J, Medeiros LJ, Bueso-Ramos CE, Loghavi SJournal of the National Comprehensive Cancer Network : JNCCNA Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. J Natl Compr Canc Netw. 2020 10; 18(10):1300-1304.J Natl Compr Canc Netw2020-10-01T00:00:002020A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications.33032648Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NGJournal of hematology & oncologyOutcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2020 10 08; 13(1):132.J Hematol Oncol2020-10-08T00:00:002020Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.Authorship 100329818Authorship 10036519Authorship 10037357Authorship 1003746733087716Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi KNature communicationsClonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 10 21; 11(1):5327.Nat Commun2020-10-21T00:00:002020Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.33112940Chifotides HT, Masarova L, Alfayez M, Daver N, Alvarado Y, Jabbour E, Konopleva M, Kantarjian HM, Patel KP, DiNardo CD, Verstovsek SBlood advancesOutcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors. Blood Adv. 2020 11 10; 4(21):5336-5342.Blood Adv2020-11-10T00:00:002020Outcome of patients with IDH1/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors.33119202Shoukier M, Kadia T, Konopleva M, Alotaibi AS, Alfayez M, Loghavi S, Patel KP, Kanagal-Shamanna R, Cortes J, Samra B, Jabbour E, Garcia-Manero G, Takahashi K, Pierce S, Short NJ, Yilmaz M, Sasaki K, Masarova L, Pemmaraju N, Borthakur G, Kantarjian HM, Ravandi F, DiNardo CD, Daver NCancerClinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations. Cancer. 2021 02 01; 127(3):381-390.Cancer2020-10-29T00:00:002020Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations.33119213Ramani NS, Chen H, Broaddus RR, Lazar AJ, Luthra R, Medeiros LJ, Patel KP, Rashid A, Routbort MJ, Stewart J, Tang Z, Bassett R, Manekia J, Barkoh BA, Dang H, Roy-Chowdhuri SCancer cytopathologyUtilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers. Cancer Cytopathol. 2021 05; 129(5):374-382.Cancer Cytopathol2020-10-29T00:00:002020Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.Authorship 10050696Authorship 10053037Authorship 10053451833211826Short NJ, Montalban-Bravo G, Hwang H, Ning J, Franquiz MJ, Kanagal-Shamanna R, Patel KP, DiNardo CD, Ravandi F, Garcia-Manero G, Takahashi K, Konopleva M, Daver N, Issa GC, Andreeff M, Kantarjian H, Kadia TMBlood advancesPrognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020 11 24; 4(22):5681-5689.Blood Adv2020-11-24T00:00:002020Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia.33214561Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi KNature communicationsPublisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2020 Nov 19; 11(1):5996.Nat Commun2020-11-19T00:00:002020Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.33189964Fang H, Medeiros LJ, Tang Z, Wang W, Ok CY, Patel KP, Khoury JD, Thakral BAnnals of diagnostic pathologyFrom the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. Ann Diagn Pathol. 2021 Feb; 50:151649.Ann Diagn Pathol2020-10-24T00:00:002020From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later.Authorship 1009901233493304Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, Chen H, Rashid A, Lazar A, Lucas FAS, Yao H, Manekia J, Dang H, Barkoh BA, Medeiros LJ, Luthra R, Roy-Chowdhuri SArchives of pathology & laboratory medicineFactors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing. Arch Pathol Lab Med. 2021 11 01; 145(11):1405-1412.Arch Pathol Lab Med2021-11-01T00:00:002021Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.Authorship 101152624Authorship 101214814Authorship 1012163933585199Bannon SA, Routbort MJ, Montalban-Bravo G, Mehta RS, Jelloul FZ, Takahashi K, Daver N, Oran B, Pemmaraju N, Borthakur G, Naqvi K, Issa G, Sasaki K, Alvarado Y, Kadia TM, Konopleva M, Shamanna RK, Khoury JD, Ravandi F, Champlin R, Kantarjian HM, Bhalla K, Garcia-Manero G, Patel KP, DiNardo CDFrontiers in oncologyNext-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations. Front Oncol. 2020; 10:582213.Front Oncol2021-01-28T00:00:002021Next-Generation Sequencing of DDX41 in Myeloid Neoplasms Leads to Increased Detection of Germline Alterations.33618432Loghavi S, DiNardo CD, Furudate K, Takahashi K, Tanaka T, Short NJ, Kadia T, Konopleva M, Kanagal-Shamanna R, Farnoud NR, Pierce S, Khoury JD, Jorgensen JL, Patel KP, Daver N, Yilmaz M, Medeiros LJ, Kantarjian H, Ravandi F, Wang SABritish journal of haematologyFlow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia. Br J Haematol. 2021 03; 192(6):1054-1063.Br J Haematol2021-02-22T00:00:002021Flow cytometric immunophenotypic alterations of persistent clonal haematopoiesis in remission bone marrows of patients with NPM1-mutated acute myeloid leukaemia.33618754Yilmaz M, Alfayez M, DiNardo CD, Borthakur G, Kadia TM, Konopleva MY, Loghavi S, Kanagal-Shamanna R, Patel KP, Jabbour EJ, Garcia-Manero G, Pemmaraju N, Pierce SA, Ghayas I, Short NJ, Montalban-Bravo G, Takahashi K, Assi R, Alotaibi AS, Ohanian M, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NGJournal of hematology & oncologyCorrection to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML. J Hematol Oncol. 2021 Feb 23; 14(1):34.J Hematol Oncol2021-02-23T00:00:002021Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML.Authorship 10134222133681815Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, Borthakur G, Konopleva M, Pierce SA, Wang SA, Tang G, Guerra V, Samra B, Pemmaraju N, Jabbour E, Short NJ, Issa GC, Ohanian M, Garcia-Manero G, Bhalla KN, Patel KP, Takahashi K, Andreeff M, Cortes JE, Kantarjian HM, Ravandi F, Daver NBlood cancer discoveryPatterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021 03; 2(2):125-134.Blood Cancer Discov2020-12-06T00:00:002020Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors.Authorship 10168161733885753Lachowiez CA, Loghavi S, Furudate K, Montalban-Bravo G, Maiti A, Kadia T, Daver N, Borthakur G, Pemmaraju N, Sasaki K, Alvarado Y, Yilmaz M, Short NJ, Chien K, Ohanian M, Pierce S, Patel KP, Jabbour E, Ravandi F, Kantarjian HM, Garcia-Manero G, Takahashi K, Konopleva MY, DiNardo CDBlood advancesImpact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax. Blood Adv. 2021 04 27; 5(8):2173-2183.Blood Adv2021-04-27T00:00:002021Impact of splicing mutations in acute myeloid leukemia treated with hypomethylating agents combined with venetoclax.Authorship 10172692133914911Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Masarova L, Naqvi K, Jabbour E, DiNardo CD, Takahashi K, Konopleva M, Pemmaraju N, Kadia TM, Ravandi F, Daver N, Borthakur G, Estrov Z, Khoury JD, Loghavi S, Soltysiak KA, Pierce S, Bueso-Ramos C, Patel KP, Verstovsek S, Kantarjian HM, Bose P, Garcia-Manero GCancerClinicopathologic correlates and natural history of atypical chronic myeloid leukemia. Cancer. 2021 09 01; 127(17):3113-3124.Cancer2021-04-29T00:00:002021Clinicopathologic correlates and natural history of atypical chronic myeloid leukemia.Authorship 10182207Authorship 10182301833972549Wang F, Morita K, DiNardo CD, Furudate K, Tanaka T, Yan Y, Patel KP, MacBeth KJ, Wu B, Liu G, Frattini M, Matthews JA, Little LD, Gumbs C, Song X, Zhang J, Thompson EJ, Kadia TM, Garcia-Manero G, Jabbour E, Ravandi F, Bhalla KN, Konopleva M, Kantarjian HM, Andrew Futreal P, Takahashi KNature communicationsLeukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nat Commun. 2021 05 10; 12(1):2607.Nat Commun2021-05-10T00:00:002021Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.33972555Morita K, Wang F, Jahn K, Hu T, Tanaka T, Sasaki Y, Kuipers J, Loghavi S, Wang SA, Yan Y, Furudate K, Matthews J, Little L, Gumbs C, Zhang J, Song X, Thompson E, Patel KP, Bueso-Ramos CE, DiNardo CD, Ravandi F, Jabbour E, Andreeff M, Cortes J, Bhalla K, Garcia-Manero G, Kantarjian H, Konopleva M, Nakada D, Navin N, Beerenwinkel N, Futreal PA, Takahashi KNature communicationsAuthor Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. Nat Commun. 2021 May 10; 12(1):2823.Nat Commun2021-05-10T00:00:002021Author Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics.Authorship 1020909334117074Quesada AE, Luthra R, Jabbour E, Patel KP, Khoury JD, Tang Z, Alvarez H, Mallampati S, Garcia-Manero G, Montalban-Bravo G, Medeiros LJ, Kanagal-Shamanna RCold Spring Harbor molecular case studiesIncidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy. Cold Spring Harb Mol Case Stud. 2021 06; 7(3).Cold Spring Harb Mol Case Stud2021-06-11T00:00:002021Incidental identification of inv(16)(p13.1q22)/CBFB-MYH11 variant transcript in a patient with therapy-related acute myeloid leukemia by routine leukemia translocation panel screen: implications for diagnosis and therapy.Authorship 102452331Authorship 10245952534226673Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RNModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncEpstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol. 2021 12; 34(12):2154-2167.Mod Pathol2021-07-05T00:00:002021Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship.34233450Homan CC, King-Smith SL, Lawrence DM, Arts P, Feng J, Andrews J, Armstrong M, Ha T, Dobbins J, Drazer MW, Yu K, B?d?r C, Cantor A, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fr?hling S, Fitzgibbon J, Klco JM, Kr?mer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Liu P, Godley LA, Schreiber AW, Hahn CN, Scott HS, Brown ALHaematologicaThe RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica. 2021 11 01; 106(11):3004-3007.Haematologica2021-11-01T00:00:002021The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy.Authorship 1028980334479626Aitken MJL, Ravandi F, Patel KP, Short NJJournal of hematology & oncologyPrognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia. J Hematol Oncol. 2021 09 03; 14(1):137.J Hematol Oncol2021-09-03T00:00:002021Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.Authorship 10307811034588432Issa GC, Zarka J, Sasaki K, Qiao W, Pak D, Ning J, Short NJ, Haddad F, Tang Z, Patel KP, Cuglievan B, Daver N, DiNardo CD, Jabbour E, Kadia T, Borthakur G, Garcia-Manero G, Konopleva M, Andreeff M, Kantarjian HM, Ravandi FBlood cancer journalPredictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements. Blood Cancer J. 2021 09 29; 11(9):162.Blood Cancer J2021-09-29T00:00:002021Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.Authorship 1031794234668451Ramos Perez JM, Patel KP, Loghavi S, Garcia-Manero G, Borthakur G, Jabbour E, Wierda W, Pierce S, Brandt M, Kornblau S, Kadia T, Daver N, DiNardo CD, Jain N, Yilmaz M, Short N, Verstovsek S, Ferrajoli A, Andreeff M, Konopleva M, Rivera D, McCue D, Kantarjian HM, Ravandi FLeukemia & lymphomaValue of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy. Leuk Lymphoma. 2022 03; 63(3):672-675.Leuk Lymphoma2021-10-20T00:00:002021Value of measurable residual disease monitoring in patients with acute promyelocytic leukemia in the era of frontline 'chemotherapy-free' therapy.Authorship 10331584Authorship 103334911Authorship 1034049834771519Yang RK, Toruner GA, Wang W, Fang H, Issa GC, Wang L, Quesada AE, Thakral B, Patel KP, Peng G, Liu S, Yin CC, Borthakur G, Tang Z, Wang SA, Miranda RN, Khoury JD, Medeiros LJ, Tang GCancersCBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management. Cancers (Basel). 2021 Oct 26; 13(21).Cancers (Basel)2021-10-26T00:00:002021CBFB Break-Apart FISH Testing: An Analysis of 1629 AML Cases with a Focus on Atypical Findings and Their Implications in Clinical Diagnosis and Management.34823075Khanlari M, Wang X, Loghavi S, Wang SA, Li S, Thakral B, Bueso-Ramos CE, Yin CC, Kanagal-Shamanna R, Khoury JD, Patel KP, Popat UR, Medeiros LJ, Konoplev SAnnals of diagnostic pathologyValue and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol. 2022 Feb; 56:151860.Ann Diagn Pathol2021-11-17T00:00:002021Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation.34804623Del Valle Estopinal M, Middleton LP, Esmaeli B, Patel KP, Nowroozizadeh S, Williams MDCase reports in pathologyPrimary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/?-Catenin Complex and Associated Genetic Alterations. Case Rep Pathol. 2021; 2021:6628150.Case Rep Pathol2021-11-11T00:00:002021Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Clinicopathologic Analysis with Evaluation of the E-Cadherin/?-Catenin Complex and Associated Genetic Alterations.Authorship 103665118Authorship 10367291134989420Jelloul FZ, Yang RK, Wang P, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda WG, Jain N, Thompson PA, Luthra R, Medeiros LJ, Patel KPAmerican journal of hematologyNon-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis. Am J Hematol. 2022 03 01; 97(3):E100-E102.Am J Hematol2022-01-21T00:00:002022Non-coding NOTCH1 mutations in chronic lymphocytic leukemia negatively impact prognosis.34992253El Hussein S, DiNardo CD, Takahashi K, Khoury JD, Fang H, Furudate K, Lyapichev KA, Garces S, Kanagal-Shamanna R, Ok CY, Patel KP, Routbort MJ, Ravandi F, Medeiros LJ, Wang SA, Loghavi SBone marrow transplantationAcquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant. 2022 03; 57(3):370-376.Bone Marrow Transplant2022-01-07T00:00:002022Acquired WT1 mutations contribute to relapse of NPM1-mutated acute myeloid leukemia following allogeneic hematopoietic stem cell transplant.Authorship 10404603435074072Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Mantle Cell Research Group, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang LThe Lancet. OncologyIbrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol. 2022 03; 23(3):406-415.Lancet Oncol2022-01-21T00:00:002022Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.Authorship 104401517Authorship 1044443435430388Jelloul FZ, Yang R, Garces S, Kanagal-Shamanna R, Ok CY, Loghavi S, Routbort MJ, Zuo Z, Yin CC, Floyd K, Bassett RL, Wierda W, Jain N, Thompson P, Luthra R, Medeiros LJ, Patel KPLeukemia researchLandscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia. Leuk Res. 2022 05; 116:106827.Leuk Res2022-03-21T00:00:002022Landscape of NOTCH1 mutations and co-occurring biomarker alterations in chronic lymphocytic leukemia.35467000Zaleski MP, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Routbort MJ, Kamat AM, Gao J, Siefker-Radtke A, Czerniak B, Guo CCAmerican journal of clinical pathologyDistinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.Am J Clin Pathol2022-08-04T00:00:002022Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma.Authorship 104481511Authorship 10450276Authorship 10451511135489185Fang H, Toruner GA, Tang Z, Tang G, Weissferdt A, Tashakori M, El Hussein S, Thakral B, Quesada AE, Wang W, Patel KP, Garcia-Manero G, Medeiros LJ, Bueso-Ramos CE, Jelloul FZAnnals of diagnostic pathologyPrimary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases. Ann Diagn Pathol. 2022 Aug; 59:151951.Ann Diagn Pathol2022-04-20T00:00:002022Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and TP53 mutation: A report of two cases.35504958Sakhdari A, Class C, Montalban-Bravo G, Sasaki K, Bueso-Ramos CE, Patel KP, Routbort MJ, Loghavi S, Ok CY, Quesada A, Khoury JD, Konoplev SN, Kantarjian HP, Garcia-Manero G, Medeiros LJ, Kanagal-Shamanna RModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncImmunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes. Mod Pathol. 2022 09; 35(9):1212-1219.Mod Pathol2022-05-03T00:00:002022Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.35511670Fang H, Wang SA, Khoury JD, El Hussein S, Kim DH, Tashakori M, Tang Z, Li S, Hu Z, Jelloul FZ, Patel KP, McDonnell TJ, Kadia T, Medeiros LJ, Wang WHaematologicaPure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases. Haematologica. 2022 09 01; 107(9):2232-2237.Haematologica2022-09-01T00:00:002022Pure erythroid leukemia is characterized by biallelic TP53 inactivation and abnormal p53 expression patterns in de novo and secondary cases.23940084Alayed K, Patel KP, Konoplev S, Singh RR, Routbort MJ, Reddy N, Pemmaraju N, Zhang L, Shaikh AA, Aladily TN, Jain N, Luthra R, Medeiros LJ, Khoury JDAmerican journal of hematologyTET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow. Am J Hematol. 2013 Dec; 88(12):1055-61.Am J Hematol2013-09-30T00:00:002013TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.Authorship 1045678735533262Short NJ, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour EBlood advancesHigh-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. Blood Adv. 2022 07 12; 6(13):4006-4014.Blood Adv2022-07-12T00:00:002022High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse.Authorship 1047947435690645Tashakori M, Khoury JD, Routbort MJ, Patel KP, Wang SA, Ok CY, El-Hussein S, Kanagal-Shamanna R, Luthra R, Hu S, Lin P, Pemmaraju N, Bose P, Verstovsek S, Bueso-Ramos CE, Medeiros LJ, Loghavi SModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations. Mod Pathol. 2022 11; 35(11):1677-1683.Mod Pathol2022-06-11T00:00:002022Clinicopathologic spectrum of myeloid neoplasms with concurrent myeloproliferative neoplasm driver mutations and SRSF2 mutations.Authorship 10489394135732831Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, Bejar R, Berti E, Busque L, Chan JKC, Chen W, Chen X, Chng WJ, Choi JK, Colmenero I, Coupland SE, Cross NCP, De Jong D, Elghetany MT, Takahashi E, Emile JF, Ferry J, Fogelstrand L, Fontenay M, Germing U, Gujral S, Haferlach T, Harrison C, Hodge JC, Hu S, Jansen JH, Kanagal-Shamanna R, Kantarjian HM, Kratz CP, Li XQ, Lim MS, Loeb K, Loghavi S, Marcogliese A, Meshinchi S, Michaels P, Naresh KN, Natkunam Y, Nejati R, Ott G, Padron E, Patel KP, Patkar N, Picarsic J, Platzbecker U, Roberts I, Schuh A, Sewell W, Siebert R, Tembhare P, Tyner J, Verstovsek S, Wang W, Wood B, Xiao W, Yeung C, Hochhaus ALeukemiaThe 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic?Neoplasms. Leukemia. 2022 07; 36(7):1703-1719.Leukemia2022-06-22T00:00:002022The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic?Neoplasms.Authorship 1049759535787095Senapati J, Verstovsek S, Masarova L, Pemmaraju N, Patel KP, Montalban-Bravo G, Pierce SA, Zhou L, Garcia-Manero G, Kantarjian HM, Bose PLeukemia & lymphomaImpact of SF3B1 mutation in myelofibrosis. Leuk Lymphoma. 2022 11; 63(11):2701-2705.Leuk Lymphoma2022-07-05T00:00:002022Impact of SF3B1 mutation in myelofibrosis.Authorship 106015810Authorship 105571213Authorship 10570537Authorship 105661119Authorship 10545134Authorship 105774411Authorship 105751712Authorship 105667411Authorship 105690410Authorship 10607601636671709Zuo Z, Medeiros LJ, Garces S, Routbort MJ, Ok CY, Loghavi S, Kanagal-Shamanna R, Jelloul FZ, Garcia-Manero G, Chien KS, Patel KP, Luthra R, Yin CCBiologyConcurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms. Biology (Basel). 2022 Dec 21; 12(1).Biology (Basel)2022-12-21T00:00:002022Concurrent Mutations in SF3B1 and PHF6 in Myeloid Neoplasms.36054614Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Issa G, Furudate K, Tanaka T, Pierce S, Tang G, Patel KP, Medeiros J, Abbas HA, Haddad F, Hammond D, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Pemmaraju N, Konopleva M, Garcia-Manero G, Ravandi F, Kadia TM, Loghavi S, DiNardo CDAmerican journal of hematologyContemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment. Am J Hematol. 2022 Nov; 97(11):1443-1452.Am J Hematol2022-09-15T00:00:002022Contemporary outcomes in IDH-mutated acute myeloid leukemia: The impact of co-occurring NPM1 mutations and venetoclax-based treatment.36322818Issa GC, Bidikian A, Venugopal S, Konopleva M, DiNardo CD, Kadia TM, Borthakur G, Jabbour E, Pemmaraju N, Yilmaz M, Short NJ, Maiti A, Sasaki K, Masarova L, Pierce S, Takahashi K, Tang G, Loghavi S, Patel K, Andreeff M, Bhalla K, Garcia-Manero G, Ravandi F, Kantarjian H, Daver NBlood advancesClinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv. 2023 03 28; 7(6):933-942.Blood Adv2023-03-28T00:00:002023Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML.36130297Duncavage EJ, Bagg A, Hasserjian RP, DiNardo CD, Godley LA, Iacobucci I, Jaiswal S, Malcovati L, Vannucchi AM, Patel KP, Arber DA, Arcila ME, Bejar R, Berliner N, Borowitz MJ, Branford S, Brown AL, Cargo CA, D?hner H, Falini B, Garcia-Manero G, Haferlach T, Hellstr?m-Lindberg E, Kim AS, Klco JM, Komrokji R, Lee-Cheun Loh M, Loghavi S, Mullighan CG, Ogawa S, Orazi A, Papaemmanuil E, Reiter A, Ross DM, Savona M, Shimamura A, Skoda RC, Sol? F, Stone RM, Tefferi A, Walter MJ, Wu D, Ebert BL, Cazzola MBloodGenomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.Blood2022-11-24T00:00:002022Genomic profiling for clinical decision making in?myeloid neoplasms and acute leukemia.36230473Yang RK, Chen H, Roy-Chowdhuri S, Rashid A, Alvarez H, Routbort M, Patel KP, Luthra R, Medeiros LJ, Toruner GACancersClinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods. Cancers (Basel). 2022 Sep 20; 14(19).Cancers (Basel)2022-09-20T00:00:002022Clinical Testing for Mismatch Repair in Neoplasms Using Multiple Laboratory Methods.36054774Short NJ, Macaron W, Kadia T, Dinardo C, Issa GC, Daver N, Wang S, Jorgensen J, Nguyen D, Bidikian A, Patel KP, Loghavi S, Konopleva M, Yilmaz M, Jabbour E, Maiti A, Abbas HA, Shpall E, Popat U, Al-Atrash G, Pierce S, Kantarjian HM, Ravandi FAmerican journal of hematologyClinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission. Am J Hematol. 2022 Nov; 97(11):E408-E411.Am J Hematol2022-09-08T00:00:002022Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease?(MRD) recurrence following MRD-negative remission.36279879Jabbour E, Short NJ, Jain N, Thompson PA, Kadia TM, Ferrajoli A, Huang X, Yilmaz M, Alvarado Y, Patel KP, Garcia-Manero G, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian HThe Lancet. HaematologyHyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec; 9(12):e878-e885.Lancet Haematol2022-10-22T00:00:002022Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.36583229Shuai W, Zuo Z, Li N, Garces S, Jelloul FZ, Ok CY, Li S, Xu J, You MJ, Wang W, Rehder C, Jabbour EJ, Patel KP, Medeiros LJ, Yin CCCancerETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia. Cancer. 2023 03 15; 129(6):878-889.Cancer2022-12-29T00:00:002022ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.36683287Jabbour EJ, Sasaki K, Haddad FG, Issa GC, Garcia-Manero G, Kadia TM, Jain N, Yilmaz M, DiNardo CD, Patel KP, Kanagal-Shamanna R, Champlin R, Khouri IF, Dellasala S, Pierce SA, Kantarjian HAmerican journal of hematologyThe outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors. Am J Hematol. 2023 04; 98(4):658-665.Am J Hematol2023-01-31T00:00:002023The outcomes of patients with chronic myeloid leukemia treated with third-line BCR::ABL1 tyrosine kinase inhibitors.36087091Venugopal S, DiNardo CD, Loghavi S, Qiao W, Ravandi F, Konopleva M, Kadia T, Bhalla K, Jabbour E, Issa GC, Macaron W, Daver N, Borthakur G, Montalban-Bravo G, Yilmaz M, Patel KP, Kanagal-Shamanna R, Chien K, Maiti A, Kantarjian H, Short NJAmerican journal of hematologyDifferential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia. Am J Hematol. 2022 Dec; 97(12):1560-1567.Am J Hematol2022-09-26T00:00:002022Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia.36584716Xu J, Li S, Yin CC, Patel KP, Tang G, Wang W, Miranda RN, Garces S, Tang Z, Lin P, Medeiros LJHuman pathologyClassic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases. Hum Pathol. 2023 04; 134:114-123.Hum Pathol2022-12-28T00:00:002022Classic Hodgkin lymphoma with marked granulomatous reaction: A clinicopathologic study of 20 cases.Authorship 106338310Authorship 10630951136715486Sasaki K, Ravandi F, Kadia TM, Borthakur G, Short NJ, Jain N, Daver NG, Jabbour EJ, Garcia-Manero G, Loghavi S, Patel KP, Montalban-Bravo G, Masarova L, DiNardo CD, Kantarjian HMCancerPrediction of survival with lower intensity therapy among older patients with acute myeloid leukemia. Cancer. 2023 04 01; 129(7):1017-1029.Cancer2023-01-30T00:00:002023Prediction of survival with lower intensity therapy among older patients with acute myeloid leukemia.Authorship 1065248936884300Bazinet A, Kadia T, Short NJ, Borthakur G, Wang SA, Wang W, Loghavi S, Jorgensen J, Patel K, DiNardo C, Daver N, Alvarado Y, Haddad FG, Pierce S, Nogueras Gonzalez G, Maiti A, Sasaki K, Yilmaz M, Thompson P, Wierda W, Garcia-Manero G, Andreeff M, Jabbour E, Konopleva M, Huang X, Kantarjian H, Ravandi FBlood advancesUndetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity. Blood Adv. 2023 07 11; 7(13):3284-3296.Blood Adv2023-07-11T00:00:002023Undetectable measurable residual disease is associated with improved outcomes in AML irrespective of treatment intensity.Authorship 10663042236933995El Hussein S, Medeiros LJ, Lyapichev KA, Fang H, Jelloul FZ, Fiskus W, Chen J, Wei P, Schlette E, Xu J, Li S, Kanagal-Shamanna R, Yang H, Tang Z, Thakral B, Loghavi S, Jain N, Thompson PA, Ferrajoli A, Wierda WG, Jabbour E, Patel KP, Dabaja BS, Bhalla KN, Khoury JDPathologyImmunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.Pathology2023-02-25T00:00:002023Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma.Authorship 10674661736990279Jelloul FZ, Quesada AE, Yang RK, Li S, Wang W, Xu J, Tang G, Yin CC, Fang H, El Hussein S, Khoury J, Bassett RL, Garcia-Manero G, Manasanch EE, Orlowski RZ, Qazilbash MH, Patel KP, Medeiros LJ, Lin PModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncClinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies. Mod Pathol. 2023 06; 36(6):100166.Mod Pathol2023-03-27T00:00:002023Clinicopathologic Features of Therapy-Related Myeloid Neoplasms in Patients with Myeloma in the Era of Novel Therapies.Authorship 10696627Authorship 10702121437154083Jelloul FZ, Routbort MJ, DiNardo CD, Bueso-Ramos CE, Kanagal-Shamanna R, Thakral B, Zuo Z, Yin CC, Loghavi S, Ok CY, Wang SA, Tang Z, You MJ, Patel KP, Medeiros LJ, Quesada AEAmerican journal of hematologyDDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.Am J Hematol2023-05-08T00:00:002023DDX41 mutations in patients with non-myeloid hematologic neoplasms.37183966Short NJ, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian HAmerican journal of hematologyUltrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. Am J Hematol. 2023 08; 98(8):1196-1203.Am J Hematol2023-05-15T00:00:002023Ultrasensitive NGS MRD assessment in Ph+?ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.Authorship 107281119Authorship 107279733Authorship 10733931637422688Short NJ, Muftuoglu M, Ong F, Nasr L, Macaron W, Montalban-Bravo G, Alvarado Y, Basyal M, Daver N, Dinardo CD, Borthakur G, Jain N, Ohanian M, Jabbour E, Issa GC, Qiao W, Huang X, Kanagal-Shamanna R, Patel KP, Bose P, Ravandi F, Delumpa R, Abramova R, Garcia-Manero G, Andreeff M, Cortes J, Kantarjian HJournal of hematology & oncologyA phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents. J Hematol Oncol. 2023 07 08; 16(1):73.J Hematol Oncol2023-07-08T00:00:002023A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents.37441846Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CDBloodVenetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia. Blood. 2023 11 09; 142(19):1647-1657.Blood2023-11-09T00:00:002023Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.37406166Homan CC, Drazer MW, Yu K, Lawrence DM, Feng J, Arriola-Martinez L, Pozsgai MJ, McNeely KE, Ha T, Venugopal P, Arts P, King-Smith SL, Cheah J, Armstrong M, Wang P, B?d?r C, Cantor AB, Cazzola M, Degelman E, DiNardo CD, Duployez N, Favier R, Fr?hling S, Rio-Machin A, Klco JM, Kr?mer A, Kurokawa M, Lee J, Malcovati L, Morgan NV, Natsoulis G, Owen C, Patel KP, Preudhomme C, Raslova H, Rienhoff H, Ripperger T, Schulte R, Tawana K, Velloso E, Yan B, Kim E, Sood R, Hsu AP, Holland SM, Phillips K, Poplawski NK, Babic M, Wei AH, Forsyth C, Mar Fan H, Lewis ID, Cooney J, Susman R, Fox LC, Blombery P, Singhal D, Hiwase D, Phipson B, Schreiber AW, Hahn CN, Scott HS, Liu P, Godley LA, Brown AL, NISC Comparative Sequencing ProgramBlood advancesSomatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41. Blood Adv. 2023 10 24; 7(20):6092-6107.Blood Adv2023-10-24T00:00:002023Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41.Authorship 10758611137485584Haddad FG, Sasaki K, Bidikian A, Issa GC, Kadia T, Jain N, Alvarado Y, Short NJ, Pemmaraju N, Loghavi S, Patel KP, Kanagal-Shamanna R, Yilmaz M, Masarova L, Jabbour E, Kantarjian HAmerican journal of hematologyCharacteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era. Am J Hematol. 2023 10; 98(10):1619-1626.Am J Hematol2023-07-23T00:00:002023Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre- and post-ponatinib era.Authorship 10787841637665752Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CDAmerican journal of hematologyCharacteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023 Nov; 98(11):1780-1790.Am J Hematol2023-09-04T00:00:002023Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.Authorship 1080016937747438Diks J, Tang Z, Altan M, Anderson S, Chen H, Rashid A, Yang RK, Routbort MJ, Patel KP, Toruner GA, Medeiros LJ, Tang G, Luthra R, Roy-Chowdhuri SCancer cytopathologyDetection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization. Cancer Cytopathol. 2024 Jan; 132(1):41-49.Cancer Cytopathol2023-09-25T00:00:002023Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in?situ hybridization.Authorship 1082745637887551Iorgulescu JB, Shaw LK, Rashid A, Rao P, Mandayam S, Patel KP, Schmeler KM, Yang RK, Msaouel PCurrent oncology (Toronto, Ont.)M?llerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing. Curr Oncol. 2023 10 05; 30(10):9019-9027.Curr Oncol2023-10-05T00:00:002023M?llerian-Type Clear Cell Carcinoma of Donor Origin in a Male Patient with a Kidney Transplant: Ascertained by Molecular Testing.Authorship 10838983137948938Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RNModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncCorrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship." [Modern Pathology 34 (2021) 2154-2167]. Mod Pathol. 2023 Dec; 36(12):100355.Mod Pathol2023-11-09T00:00:002023Corrigendum to "Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship." [Modern Pathology 34 (2021) 2154-2167].38201434Zheng L, Luthra R, Alvarez HA, San Lucas FA, Duose DY, Wistuba II, Fuller GN, Ballester LY, Roy-Chowdhuri S, Sweeney KJ, Rashid A, Yang RK, Chen W, Liu A, Wu Y, Albarracin C, Patel KP, Routbort MJ, Sahin AA, Ding Q, Chen HCancersIntragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors. Cancers (Basel). 2023 Dec 19; 16(1).Cancers (Basel)2023-12-19T00:00:002023Intragenic EGFR::EGFR.E1E8 Fusion (EGFRvIII) in 4331 Solid Tumors.38216400Iorgulescu JB, Medeiros LJ, Patel KPPathologyPredictive and prognostic molecular biomarkers in lymphomas. Pathology. 2024 Mar; 56(2):239-258.Pathology2023-12-19T00:00:002023Predictive and prognostic molecular biomarkers in lymphomas.Authorship 10868423Authorship 108684517Authorship 10878421938277619Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi FJournal of clinical oncology : official journal of the American Society of Clinical OncologyAzacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 Jan 26; JCO2301911.J Clin Oncol2024-01-26T00:00:002024Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.Authorship 1088494638327755Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam FJournal of immunotherapy and precision oncologyLimited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol. 2024 Feb; 7(1):7-17.J Immunother Precis Oncol2024-02-05T00:00:002024Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing.Authorship 1089944838431521Sasaki K, Ravandi F, Kadia T, DiNardo CD, Yilmaz M, Short N, Jabbour E, Patel KP, Loghavi S, Pierce S, Borthakur G, Kantarjian HClinical lymphoma, myeloma & leukemiaOutcome of Patients With Relapsed Acute Promyelocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 Feb 03.Clin Lymphoma Myeloma Leuk2024-02-03T00:00:002024Outcome of Patients With Relapsed Acute Promyelocytic Leukemia.Authorship 10903961038468555El Dana F, Garces Narvaez SA, El-Mallawany NK, Agrusa JE, Dreyer ZE, Marcogliese AN, Elghetany MT, Punia JN, Ok CY, Patel KP, Lopez-Terrada DH, Fisher KE, Curry CVPediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology SocietyChildhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. Pediatr Dev Pathol. 2024 Mar 11; 10935266241230600.Pediatr Dev Pathol2024-03-11T00:00:002024Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge.true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professor24446311Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JDAmerican journal of hematologyBRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS. Am J Hematol. 2014 May; 89(5):499-504.Am J Hematol2014-02-10T00:00:002014BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.